AUSTRALIAN CAPITAL TERRITORY
Poisons and Drugs (Amendment) Act 1991
No. 4 of 1991
	
An Act to amend the Poisons and Drugs Act 1978
	[Notified in ACT Gazette S7: 1 March 1991]
	The Legislative Assembly for the Australian Capital Territory enacts as follows:
Short title
1.  This Act may be cited as the Poisons and Drugs (Amendment) Act 1991.
Commencement
2.  (1)  Sections 1, 2 and 3 commence on the day on which this Act is notified in the Gazette.
(2)  The remaining provisions commence on a day, or respective days, fixed by the Minister by notice in the Gazette.
(3)  If a provision referred to in subsection (2) has not commenced before the end of the period of 6 months commencing on the day on which this Act is notified in the Gazette, that provision, by force of this subsection, commences on the first day after the end of that period.
Principal Act
3.  In this Act, “Principal Act” means the Poisons and Drugs Act 1978.1
Substitution
4.  Schedules 1 to 7, inclusive, to the Principal Act are repealed and the following Schedules substituted:

	SCHEDULE 1	Section 3
Aconite (Aconitum spp)
Comfrey (Symphytum spp) for human internal use, being—
	(a)	any preparation; or
	(b)	any part of the dried plant
Croton oil
Savin, oil of
Tansy, oil of

	SCHEDULE 2	Section 3
Acetic acid (excluding its salts and derivatives) in preparations containing more than 80% of acetic acid, for therapeutic use
Aloxiprin
Antazoline in eye drops
Aspirin, except—
	(a)	when included in Schedule 4 or 6;
	(b)	in individually wrapped powders or sachets of granules each containing 650 mg or less of aspirin as the only therapeutically active constituent, other than effervescent agents, when enclosed in a primary pack that—
	(i)	contains not more than 12 such powders or sachets of granules;
	(ii)	is labelled—
		“WARNING—THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD”; or
		“CAUTION—THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED.  PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL”; and
	(iii)	includes in the directions for use, in capital letters not less than 1.5 mm in height, the warning statements—
		“CONSULT A DOCTOR BEFORE GIVING THIS MEDICINE TO CHILDREN OR TEENAGERS WITH CHICKEN POX, INFLUENZA OR FEVER”; and
		“CAUTION—DO NOT GIVE TO CHILDREN UNDER 2 YEARS OF AGE EXCEPT ON DOCTOR’S ADVICE”; or
	(c)	in tablets or capsules each containing 325 mg or less of aspirin as the only therapeutically active constituent, other than effervescent agents, when—
	(i)	packed in blister or strip packaging or in containers with a child‑resistant closure;
	(ii)	in a primary pack containing not more than 25 such tablets or capsules;
	(iii)	the pack is labelled—
		“WARNING—THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD”; or
		“CAUTION—THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED.  PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL”; and
	(iv)	includes in the directions for use, in capital letters not less than 1.5 mm in height, the warning statements—
		“CONSULT A DOCTOR BEFORE GIVING THIS MEDICINE TO CHILDREN OR TEENAGERS WITH CHICKEN POX, INFLUENZA OR FEVER”; and
		“CAUTION—DO NOT GIVE TO CHILDREN UNDER 2 YEARS OF AGE EXCEPT ON DOCTOR’S ADVICE”
Atropine (excluding atropine methonitrate)—
	(a)	in preparations containing 0.25% or less of atropine; or
	(b)	atropine sulphate, 0.6 mg tablets in packs of six, when labelled for treatment of organophosphorus poisoning
Belladonna in preparations containing 0.25% or less of the alkaloids of belladonna, calculated as hyoscyamine
Benzamine when included in—
	(a)	lozenges, pastilles, tablets or capsules containing 30 mg or less of benzamine in each;
	(b)	suppositories or bougies containing 200 mg or less of benzamine in each; or
	(c)	preparations for topical use, other than eye drops, containing 10% or less of benzamine
Benzocaine when included in—
	(a)	lozenges, pastilles, tablets or capsules containing 30 mg or less of benzocaine in each;
	(b)	suppositories or bougies containing 200 mg or less of benzocaine in each; or
	(c)	preparations for topical use, other than eye drops, containing 10% or less of benzocaine
Benzoyl peroxide in preparations for external human therapeutic use containing 5% or less of benzoyl peroxide
Benzydamine in preparations for topical use containing 3% or less of benzydamine
Bromhexine
Brompheniramine in oral preparations when compounded with one or more of the following medicaments:
	(a)	an antitussive, except codeine or dihydrocodeine;
	(b)	an expectorant;
	(c)	a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age
Buclizine in primary packs of 10 doses or less, for the prevention or treatment of motion sickness
Butylaminobenzoate when included in—
	(a)	lozenges, pastilles, tablets or capsules containing 30 mg or less of butylaminobenzoate in each;
	(b)	suppositories or bougies containing 200 mg or less of butylaminobenzoate in each; or
	(c)	preparations for topical use, other than eye drops, containing 10% or less of butylaminobenzoate
Carbaryl in preparations for external human therapeutic use containing 2% or less of carbaryl
Carbenoxolone for topical oral use
Carbetapentane, except in preparations containing 0.5% or less of carbetapentane
Chloroform in preparations for therapeutic use, except—
	(a)	when included in Schedule 4; or
	(b)	in preparations containing 0.5% or less of chloroform
Chlorpheniramine in oral preparations when compounded with one or more of the following medicaments:
	(a)	an antitussive, except codeine or dihydrocodeine;
	(b)	an expectorant;
	(c)	a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age
Cinnamedrine
Clioquinol and other halogenated derivatives of 8-hydroxyquinoline for external human use
Codeine—
	(a)	when compounded with aspirin, paracetamol or any one of their derivatives, in dosage units each containing 10 mg or less of codeine and no other analgesic substance, and—
	(i)	in tablets or capsules when packed in blister or strip packaging or in a container with a child-resistant closure; or
	(ii)	in individually wrapped powders;
and in a primary pack containing 25 or less dosage units; or
	(b)	when compounded with one or more other therapeutically active substances—
	(i)	in divided preparations containing 10 mg or less of codeine and with a recommended dose not exceeding 15 mg of codeine; or
	(ii)	in undivided preparations containing 0.25% or less of codeine and with a recommended dose not exceeding 15 mg of codeine
Creosote derived from wood, for human therapeutic use, except in preparations containing 3% or less of phenols included in this Schedule
Cyanides—see Hydrocyanic acid
DDT—see Dicophane
Dexchlorpheniramine in oral preparations when compounded with one or more of the following medicaments:
	(a)	an antitussive, except codeine or dihydrocodeine;
	(b)	an expectorant;
	(c)	a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age
Dextromethorphan when compounded with one or more other therapeutically active substances—
	(a)	in divided preparations containing 30 mg or less of dextromethorphan per dosage unit and with a recommended dose not exceeding 30 mg of dextromethorphan; or
	(b)	in undivided preparations containing 0.3% or less of dextromethorphan with a recommended dose not exceeding 30 mg of dextromethorphan
Dicophane (DDT) in preparations for human therapeutic use
Dicyclomine in preparations containing 0.1% or less of dicyclomine
Dihydrocodeine when compounded with aspirin and no other therapeutically active substance, in divided preparations containing 5 mg or less of dihydrocodeine per dosage unit and with a recommended dose not exceeding 10 mg of dihydrocodeine when—
	(a)	packed in blister or strip packaging or in a container with a child-resistant closure; and
	(b)	in a primary pack containing 25 or less dosage units
Dimenhydrinate in primary packs of 10 doses or less, for the prevention or treatment of motion sickness
Dimethisoquin in preparations for topical use
Diphemanil methylsulphate in preparations for topical use
Diphenhydramine—
	(a)	in primary packs of 10 doses or less, for the prevention or treatment of motion sickness; or
	(b)	in oral preparations when compounded with one or more of the following medicaments:
	(i)	an antitussive, except codeine or dihydrocodeine;
	(ii)	an expectorant;
	(iii)	a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age
Diphenylpyraline in oral preparations when compounded with one or more of the following medicaments:
	(a)	an antitussive, except codeine or dihydrocodeine;
	(b)	an expectorant;
	(c)	a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age
Doxylamine in oral preparations when compounded with one or more of the following medicaments:
	(a)	an antitussive, except codeine or dihydrocodeine;
	(b)	an expectorant;
	(c)	a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age
Ephedrine for internal use, for the relief of respiratory tract conditions only, when compounded with one or more other therapeutically active substances in preparations containing 30 mg or less of ephedrine per recommended dose, except in liquid preparations containing 10 mg or less of ephedrine per recommended dose
Erythrityl tetranitrate for therapeutic use
Etafedrine
Ether for therapeutic use, except—
	(a)	when included in Schedule 4; or
	(b)	in preparations containing 10% or less of ether
Ethoheptazine in preparations containing 1% or less of ethoheptazine
Ethylmorphine, when compounded with one or more other therapeutically active substances—
	(a)	in divided preparations containing 10 mg or less of ethylmorphine per dosage unit and with a recommended dose not exceeding 15 mg of ethylmorphine; or
	(b)	in undivided preparations containing 0.25% or less of ethylmorphine and with a recommended dose not exceeding 15 mg of ethylmorphine
Fluoride for human therapeutic use, being—
	(a)	sodium fluoride in preparations for ingestion containing 2.2 mg or less of sodium fluoride per dosage unit; or
	(b)	in preparations for topical use, except—
	(i)	when included in Schedule 3;
	(ii)	in dentifrices containing 1,000 mg/kg or less of fluoride ion; or
	(iii)	in other substances containing 15 mg/kg or less of fluoride ion
Gelsemium
Glutaraldehyde for human therapeutic use
Glyceryl trinitrate for therapeutic use, except when included in Schedule 4
Guaiphenesin—
	(a)	in liquid preparations containing 2% (200 mg/10 ml) or less of guaiphenesin; or
	(b)	in divided preparations containing 120 mg or less of guaiphenesin per dosage unit
Hexachlorophane in preparations for human skin cleansing purposes containing 3% or less of hexachlorophane, except  in preparations for use on infants as specified in Schedule 4
Homatropine in preparations containing 0.25% or less of homatropine
Human chorionic gonadotrophin or its antibody in pregnancy test kits
Hydroquinone (excluding monobenzone and other alkyl ethers of hydroquinone included in Schedule 4) in preparations for external human therapeutic or cosmetic use containing 2% or less of hydroquinone, except hair preparations containing 1% or less of hydroquinone
8-Hydroxyquinoline and its non-halogenated derivatives for human therapeutic use, except in preparations for external use containing 1% or less of such substances
Hyoscine (excluding hyoscine butylbromide)—
	(a)	in preparations containing 0.25% or less of hyoscine; or
	(b)	in transdermal applicators containing 2 mg or less of hyoscine
Hyoscyamine in preparations containing 0.25% or less of hyoscyamine
Hyoscyamus in preparations containing 0.25% or less of the alkaloids of hyoscyamus calculated as hyoscyamine
Iodine—
	(a)	in preparations for internal human therapeutic use containing 300 mg or more of iodine, except—
	(i)	when included in Schedule 4; or
	(ii)	when labelled, in letters not less than 1.5 mm in height—
		“CAUTION—TOTAL IODINE INTAKE MAY EXCEED RECOMMENDED LEVEL WHEN TAKING THIS PREPARATION”; and
		“WARNING—CONTAINS IODINE—DO NOT TAKE WHEN PREGNANT EXCEPT ON PHYSICIAN’S ADVICE”; or
	(b)	in preparations for external human therapeutic use containing more than 2.5% of available iodine other than as iodine salts, derivatives or iodophors
Iron compounds for human internal use, except—
	(a)	when included in Schedule 4;
	(b)	in divided preparations containing 5 mg or less of iron per dosage unit; or
	(c)	in liquid oral preparations containing 0.1% or less of iron
Isopropamide in preparations containing 2% or less of isopropamide for dermal use
Isosorbide dinitrate for therapeutic use
Lignocaine when included in—
	(a)	lozenges, pastilles, tablets or capsules containing 30 mg or less of lignocaine in each;
	(b)	suppositories or bougies containing 200 mg or less of lignocaine in each; or
	(c)	preparations for topical use, other than eye drops, containing 10% or less of lignocaine
Lindane in preparations for external human therapeutic use containing 2% or less of lindane
Lobelia—
	(a)	in divided preparations containing 2.5 mg or less of lobeline per dosage unit; or
	(b)	in undivided preparations containing 0.05% or less of lobeline;
except in preparations for smoking or burning
Lobeline—
	(a)	in divided preparations containing 2.5 mg or less of lobeline per dosage unit; or
	(b)	in undivided preparations containing 0.05% or less of lobeline;
except in preparations for smoking or burning
Luteinising hormone or its antibody in human ovulation test kits
Maldison in preparations for external human therapeutic use containing 2% or less of maldison
Mebendazole for human therapeutic use
Mercuric oxide in ointments for human ocular use
Mercury organic compounds for topical human therapeutic use in preparations containing 0.5% or less of mercury
Methoxamine, except in preparations for external use containing 1% or less of methoxamine
Methoxyphenamine
Methylephedrine
Miconazole for human use in preparations containing 2% or less of miconazole for treatment of fungal infections of the skin
Naphazoline
Naproxen in packs of 12 or less tablets or capsules for treatment of spasmodic dysmenorrhoea
Niclosamide for human therapeutic use
Nitric esters of polyhydric alcohols for therapeutic use, except when separately specified in these Schedules
Noscapine
Oxethazaine in preparations for internal use
Oxymetazoline
Papaverine, except when included in Schedule 4
Paracetamol, except—
	(a)	when included in Schedule 4;
	(b)	in individually wrapped powders or sachets of granules each containing 1000 mg or less of paracetamol as the only therapeutically active constituent other than effervescent agents when—
	(i)	the pack is labelled—
		“WARNING—THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD”; or
		“CAUTION—THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED.  PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL”; and
	(ii)	in a primary pack containing not more than 12 such powders or sachets;
unless the pack is labelled for the treatment of children under 7 years of age; or
	(c)	tablets or capsules each containing 500 mg or less of paracetamol as the only therapeutically active constituent other than effervescent agents when—
	(i)	the pack is labelled—
		“WARNING—THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD”; or
		“CAUTION—THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED.  PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL”;
	(ii)	packed in blister or strip packaging or in containers with a child‑resistant closure; and
	(iii)	in a primary pack containing not more than 25 such tablets or capsules;
unless the pack is labelled for the treatment of children under 7 years of age
Phedrazine
Phenazone for external use
Pheniramine—
	(a)	in primary packs of 10 doses or less, for the prevention or treatment of motion sickness; or
	(b)	in oral preparations when compounded with one or more of the following medicaments:
	(i)	an antitussive, except codeine or dihydrocodeine;
	(ii)	an expectorant;
	(iii)	a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age
Phenol, or any homologue of phenol boiling below 220oC, for human therapeutic use, except in preparations containing 3% or less of such substances
Phenylenediamines and alkylated phenylenediamines for therapeutic use
Phenylephrine, except—
	(a)	when included in Schedule 4;
	(b)	preparations containing 0.5% or less of phenylephrine; or
	(c)	preparations for external use containing 1% or less of phenylephrine
Pholcodine when compounded with one or more other therapeutically active substances—
	(a)	in divided preparations containing 10 mg or less of pholcodine per dosage unit and with a recommended dose not exceeding 25 mg of pholcodine; or
	(b)	in undivided preparations containing 0.5% or less of pholcodine and with a recommended dose not exceeding 25 mg of pholcodine
Podophyllotoxin for external human therapeutic use in preparations containing 2% or less of podophyllotoxin
Podophyllum resin (podophyllin) for external human therapeutic use in preparations containing 10% or less of podophyllin
Potassium chlorate for therapeutic use except in preparations containing 10% or less of potassium chlorate
Pramoxine when included in preparations for external use, other than eye drops, containing 1% or less of pramoxine
Procyclidine in preparations containing 5% or less of procyclidine for dermal use
Promethazine—
	(a)	in primary packs of 10 doses or less, for the prevention or treatment of motion sickness; or
	(b)	in oral preparations when compounded with one or more of the following medicaments:
	(i)	an antitussive, except codeine or dihydrocodeine;
	(ii)	an expectorant;
	(iii)	a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age
Propantheline in preparations for topical use
Pseudoephedrine—
	(a)	in preparations containing 60 mg or less of pseudoephedrine per recommended dose; or
	(b)	in slow-release preparations containing 120 mg or less of pseudoephedrine per recommended dose, for which approval for the slow-release characteristic has been granted by the Commonwealth Department of Community Services and Health;
except when included in Schedule 4
Pyrantel for human therapeutic use
Pyrithione zinc for human therapeutic use, except—
	(a)	in semi-solid hair preparations; or
	(b)	in shampoos containing 2% or less of pyrithione zinc when labelled—
		“KEEP OUT OF EYES”; or
		“IF IN EYES, RINSE WELL WITH WATER”
Salicylamide, except when included in Schedule 4
Silver salts for therapeutic use, except—
	(a)	chewing tablets containing 5 mg or less of silver per tablet when the pack is labelled—
		“WARNING—OVERUSE MAY STAIN THE SKIN OR MOUTH”; or
	(b)	solutions containing 0.3% or less of silver when the pack is labelled—
		“WARNING—OVERUSE MAY STAIN THE SKIN OR MOUTH”
Sodium cromoglycate in nasal preparations for topical use
Sodium nitrite for therapeutic use
Staphisagria, except in preparations containing 0.2% or less of staphisagria
Stramonium in preparations containing 0.25% or less of the alkaloids calculated as hyoscyamine, except preparations for smoking or burning
Tetrahydrozoline
Thenyldiamine—
	(a)	in nasal preparations for topical use; or
	(b)	in oral preparations when compounded with one or more of the following medicaments:
	(i)	an antitussive except codeine or dihydrocodeine;
	(ii)	an expectorant;
	(iii)	a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age
Tramazoline
Trimeprazine in oral preparations when compounded with one or more of the following medicaments:
	(a)	an antitussive except codeine or dihydrocodeine;
	(b)	an expectorant;
	(c)	a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age
Triprolidine in oral preparations when compounded with one or more of the following medicaments:
	(a)	an antitussive except codeine or dihydrocodeine;
	(b)	an expectorant;
	(c)	a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age
Tymazoline
Xylometazoline

	SCHEDULE 3	Section 3
Acepifylline in liquid oral preparations
Adrenaline in preparations containing 1% or less of adrenaline, except in preparations containing 0.02% or less of adrenaline
Aminophylline in liquid oral preparations
Amyl nitrite
Azatadine in oral preparations
Benzoyl peroxide in preparations containing 10% or less of benzoyl peroxide for external human therapeutic use, except when included in Schedule 2
Brompheniramine in oral preparations, except when included in Schedule 2
Buclizine in oral preparations, except when included in Schedule 2
Butyl nitrite
Chlorofluorocarbons alone or in combination with other propellants or refrigerants in liquefied gas form for therapeutic use
Chlorpheniramine in oral preparations, except when included in Schedule 2
Clemastine in oral preparations
Clotrimazole for human use in preparations containing 1% or less of clotrimazole, for treatment of fungal infections of the skin
Codeine when—
	(a)	compounded with aspirin, paracetamol or any one of their derivatives and no other analgesic substance; and
	(b)	in divided preparations containing 10 mg or less of codeine per dosage unit with a recommended dose not exceeding 15 mg of codeine;
except when included in Schedule 2
Cyproheptadine in oral preparations
Dexchlorpheniramine in oral preparations, except when included in Schedule 2
Dihydrocodeine when compounded with one or more other therapeutically active substances—
	(a)	in divided preparations containing 10 mg or less per dosage unit and with a recommended dose not exceeding 15 mg of dihydrocodeine; or
	(b)	in undivided preparations containing 0.25% or less of dihydrocodeine with a recommended dose not exceeding 15 mg of dihydrocodeine;
except when included in Schedule 2
Dimenhydrinate in oral preparations, except when included in Schedule 2
Dimethindene in oral preparations
Diphenhydramine in oral preparations, except when included in Schedule 2
Diphenylpyraline in oral preparations, except when included in Schedule 2
Dithranol for human therapeutic use
Doxylamine in oral preparations, except when included in Schedule 2
Econazole for human use in preparations containing 1% or less of econazole for treatment of fungal infections of the skin
Ephedrine for internal use, for the relief of respiratory tract conditions only, when compounded with one or more other therapeutically active substances, except—
	(a)	when included in Schedule 2; or
	(b)	in liquid preparations containing 10 mg or less of ephedrine per recommended dose
Fenoterol in metered aerosols delivering 200 micrograms or less of fenoterol per metered dose
Flavoxate
Fluorides in dentifrices containing more than 1000 mg/kg of fluoride ion
Fluorocarbons alone or in combination with other propellants or refrigerants in liquefied gas form for therapeutic use
Folic acid for human therapeutic use, except in preparations containing 500 micrograms or less of folic acid per recommended daily dose
Folinic acid for human therapeutic use, except in preparations containing 500 micrograms or less of folinic acid per recommended daily dose
Hydrocortisone (excluding its salts and derivatives other than hydrocortisone acetate) as the only therapeutically active substance in preparations for dermal use containing 0.5% or less of hydrocortisone in packs containing 30 grams or less where the labelling warns against—
	(a)	contact with the eyes; or
	(b)	use for acne;
and against use, except on medical advice—
	(c)	on children under 2 years of age;
	(d)	for more than 7 days; or
	(e)	under occlusive dressings
Ibuprofen as the only therapeutically active substance in divided preparations for oral use containing 200 mg or less of ibuprofen per dosage unit in a pack containing 50 or less dosage units and with a recommended daily dose not exceeding 1200 mg of ibuprofen
Idoxuridine in preparations containing 0.5% or less of idoxuridine for dermal use
Insulin
Isoconazole for human use in preparations containing 1% or less of isoconazole, for treatment of fungal infections of the skin
Loperamide in packs of 8 dosage units or less, each dosage unit containing 2 mg or less of loperamide
Mefenamic acid in packs of 30 or less capsules for treatment of spasmodic dysmenorrhoea
Mepyramine in oral preparations
Methdilazine in oral preparations
Miconazole for human use in topical preparations containing 2% or less of miconazole for the treatment of oral candidiasis
Nicotine in chewing tablets containing 2 mg or less of nicotine per tablet for use as an aid in withdrawal from tobacco smoking
Nitrofurazone in preparations for dermal use containing 0.2% or less of nitrofurazone
Nystatin in preparations for topical use for treatment of candidal infections only
Octyl nitrite
Pheniramine in oral preparations, except when included in Schedule 2
Phenylpropanolamine in preparations containing 25 mg or less per recommended dose of phenylpropanolamine when labelled only for the relief of coughs or colds
Phenyltoloxamine in oral preparations
Podophyllotoxin for external human therapeutic use in preparations containing 4% or less of podophyllotoxin, except when included in Schedule 2
Podophyllum resin (podophyllin) for external human therapeutic use in preparations containing 20% or less of podophyllin, except when included in Schedule 2
Promethazine in oral preparations, except when included in Schedule 2
Pseudoephedrine, except when included in Schedule 2 or 4
Quinine for human internal therapeutic use, except in liquids containing 40 mg/litre or less of quinine
Salbutamol—
	(a)	in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or
	(b)	in capsules of dry powder for inhalation delivering 200 micrograms or less of salbutamol per dose
Santonin
Terbutaline in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose
Terfenadine as the only therapeutically active substance in divided preparations for oral use containing 60 mg or less of terfenadine per dosage unit in a pack containing 20 or less dosage units

Thenyldiamine in oral preparations, except when included in Schedule 2
Theophylline in liquid oral preparations
Tioconazole for human use in preparations containing 1% or less of tioconazole for treatment of fungal infections of the skin
Tretinoin for external human therapeutic use
Trimeprazine—
	(a)	in solid oral preparations; or
	(b)	in liquid oral preparations containing 10 mg or less of trimeprazine per 5 ml;
except when included in Schedule 2
Triprolidine in oral preparations, except when included in Schedule 2

	SCHEDULE 4	Section 3
Acebutolol
Acepifylline, except when included in Schedule 3
Acepromazine
Acetanilide and alkyl acetanilides, for human therapeutic use
Acetazolamide
Acetohexamide
Acetylcholine
Acetylcysteine
Acetyldihydrocodeine when compounded with one or more other medicaments—
	(a)	in divided preparations containing not more than 100 mg of acetyldihydrocodeine per dosage unit; or
	(b)	in undivided preparations with a concentration of not more than 2.5% of acetyldihydrocodeine
Acetylmethyldimethyloximidophenylhydrazine
Actinomycin D (dactinomycin)
Acyclovir
Adiphenine
Adrenaline, except—
	(a)	when included in Schedule 3; or
	(b)	in preparations containing 0.02% or less of adrenaline
Alclometasone
Alcuronium salts
Allopurinol
Allyloestrenol
Alphadolone
Alphaxalone
Alprazolam
Alprenolol
Alprostadil
Amantadine
Ambenonium
Ambucetamide
Ambutonium
Amethocaine
Amikacin
Amiloride
3-Aminobenzoic acid ethyl ester methanesulphonate
Aminocaproic acid
Aminoglutethimide
Aminometradine
Aminophenazone and its derivatives, for the treatment of animals
Aminophylline, except when included in Schedule 3
Aminopterin
4-Aminopyridine
Aminorex
Aminosalicylic acid
Amiodarone
Amiphenazole
Amisometradine
Amitriptyline
Amodiaquine
Amoxycillin
Amphomycin
Amphotericin
Ampicillin
Amsacrine
Amylobarbitone when packed and labelled for injection
Amylocaine
Anabolic steroidal agents, except when separately specified in these Schedules
Angiotensin amide
Antazoline, except when included in Schedule 2
Antibiotics, except—
	(a)	when separately specified in these Schedules; or
	(b)	nisin
Antigens for human therapeutic use
Antihistamines, except—
	(a)	when included in Schedule 2 or 3; or
	(b)	when separately specified in this Schedule
Antimony organic compounds for therapeutic use
Apomorphine
Aprotinin
Arsenic—see Thiacetarsamide
Aspirin—
	(a)	when combined with caffeine, paracetamol or salicylamide or any derivative of these substances; or
	(b)	for injection
Astemizole
Atenolol
Atracurium besylate
Atropine, except when included in Schedule 2
Auranofin
Avoparcin, except when packed and labelled for use as an animal feed additive
Azaperone
Azapetine
Azatadine, except when included in Schedule 3
Azlocillin
Aztreonam
Bacampicillin
Bacitracin, except—
	(a)	when included in Schedule 6;
	(b)	in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances; or
	(c)	in milk replacers for calves and starter rations for pigs containing 100 mg/kg or less of antibiotic substances
Baclofen
Bamipine
Barbiturates, except when separately specified in these Schedules
Beclamide
Belladonna, except when included in Schedule 2
Bemegride
Benactyzine and other substances structurally derived from diphenylmethane with ataractic properties when used for therapeutic purposes
Bendrofluazide
Benorylate
Benserazide
Benzamine, except when included in Schedule 2
Benzhexol
Benzilonium
Benzocaine, except when included in Schedule 2
Benzodiazepine derivatives, except when separately specified in these Schedules
Benzoyl peroxide in preparations for external human therapeutic use, except when included in Schedule 2 or 3
Benzphetamine
Benztropine
Benzydamine, except when included in Schedule 2
Benzylpenicillin (including procaine penicillin), except when included in Schedule 6
Betahistine
Bethanechol chloride
Bethanidine
Bifonazole
Biperiden
Bismuth compounds for human therapeutic or cosmetic use, except—
	(a)	bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5% or less;
	(b)	bismuth oxychloride in cosmetics; or
	(c)	bismuth formic iodide or bismuth subiodide in dusting powders containing 3% or less of bismuth
Bleomycin
Boron for human therapeutic use—
	(a)	for internal use
	(b)	in glycerines or honeys of borax or boric acid;
	(c)	in dusting powders for paediatric use; or
	(d)	as a therapeutically active ingredient in other preparations for dermal use except—
	(i)	in antifungal preparations; or
	(ii)	in preparations containing 0.1% or less of boron
Bretylium
Bromazepam
Bromides, inorganic, for therapeutic use
Bromocriptine
Bromoform for therapeutic use
Brompheniramine, except when included in Schedule 2 or 3
Bromvaletone
Buclizine, except when included in Schedule 2 or 3
Bufexamac, except—
	(a)	in preparations for dermal use containing 5% or less of bufexamac; or
	(b)	in suppositories
Bumetanide
Bupivacaine
Buprenorphine
Buspirone
Busulphan
Butacaine
Butylaminobenzoate, except when included in Schedule 2
Butylchloral hydrate
Calcitonin
Calcitriol
Calcium carbimide for therapeutic use
Camphorated oil excluding admixtures
Camphotamide
Candicidin
Canine tick anti-serum
Cantharidin
Capreomycin
Captodiame
Captopril
Capuride
Caramiphen
Carbachol
Carbamazepine
Carbaryl for human therapeutic use, except when included in Schedule 2
Carbazochrome
Carbenicillin
Carbenoxolone, except when included in Schedule 2
Carbidopa
Carbimazole
Carbocromen
Carboplatin
Carbromal
Cardiac glycosides, except when separately specified in these Schedules
Carindacillin
Carmustine
Carnidazole for the treatment of pigeons
Catalin
Cathine
Cefaclor
Cefoperazone
Cefotaxime
Cefotetan
Cefoxitin
Ceftazidime
Ceftriaxone
Cephacetrile
Cephadroxil for the treatment of animals
Cephalexin
Cephaloridine
Cephalothin
Cephamandole
Cephapirin
Cephazolin
Cephradine
Chenodeoxycholic acid
Chloral formamide
Chloral hydrate, except in preparations for topical use containing 2% or less of chloral hydrate
a-Chloralose—see Chloralose
Chloralose, except when included in Schedule 6
Chlorambucil
Chloramphenicol
Chlorazanil
Chlorbutol in preparations for human oral use, except in preparations containing 0.5% or less of chlorbutol as a preservative
Chlorcyclizine
Chlordiazepoxide
Chlormerodrin
Chlormethiazole
Chlormezanone
Chloroform for use in anaesthesia
2-(4-Chlorophenyl)-1,2,4-triazole [5,1a]-isoquinoline for the treatment of animals
Chloroquine
Chlorothiazide
Chlorpheniramine, except when included in Schedule 2 or 3
Chlorphentermine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortetracycline, except when included in Schedule 6
Chlorthalidone
Chlorzoxazone
Cholestyramine for human therapeutic use
Chymopapain, injection for human therapeutic use
Ciclacillin
Cilastatin
Cimetidine
Cinchocaine
Cinoxacin
Ciprofloxacin
Cisapride
Cisplatin
Clanobutin for the treatment of animals
Clavulanic acid
Clemastine, except when included in Schedule 3
Clemizole
Clenbuterol for the treatment of animals
Clidinium
Clindamycin
Clobazam
Clobetasone-17-butyrate
Clofenamide
Clofibrate
Clomiphene
Clomipramine
Clomocycline
Clonazepam
Clonidine
Clopamide
Cloprostenol for the treatment of animals
Clorazepate
Clorexolone
Clorprenaline
Clotrimazole, except when included in Schedule 3 or 6
Cloxacillin
Clozapine
Codeine when compounded with one or more other therapeutically active substances—
	(a)	in divided preparations containing 30 mg or less of codeine per dosage unit; or
	(b)	in undivided preparations containing 1% or less of codeine;
except when included in Schedule 2 or 3
Colaspase
Colchicine
Colestipol for human therapeutic use
Colistin
Cortisone and steroid suprarenal cortical hormones, except hydrocortisone in Schedule 3
Crystal violet for human therapeutic use
Curare
Cyclandelate
Cyclizine
Cyclofenil
Cyclopenthiazide
Cyclopentolate
Cyclophosphamide
Cyclopropane for therapeutic use
Cycloserine
Cyclosporin
Cyclothiazide
Cycrimine
Cyproheptadine, except when included in Schedule 3
Cyproterone
Cytarabine
Dacarbazine
Danazol
Dantrolene
Dapsone
Daunorubicin
Deanol
Debrisoquine
Demecarium bromide
Demeclocycline
Desipramine
Desmopressin (DDAVP)
Detomidine for the treatment of animals
Dexchlorpheniramine, except when included in Schedule 2 or 3
Dexfenfluramine
Dextromethorphan, except when included in Schedule 2
Dextropropoxyphene—
	(a)	in divided preparations containing 135 mg or less of dextropropoxyphene per dosage unit; or
	(b)	in liquid preparations containing 2.5% or less of dextropropoxyphene
Dextrorphan
Diazepam
Diazoxide
Dibenzepin
trans-4-((3,5-Dibromo-2-hydroxybenzyl)-amino) cyclohexanol hydrochloride monohydrate (sputolysin), except when included in Schedule 6
Dichloralphenazone
Dichlorphenamide
Diclofenac
Dicyclomine, except when included in Schedule 2
Dienoestrol
Diethazine
Diethylcarbamazine for human therapeutic use
Diethylpropion
Difenoxin in preparations containing, per dosage unit, 0.5 mg or less of difenoxin and a quantity of atropine sulphate equivalent to at least 5% of the dose of difenoxin
Diflunisal
Digitalis and its glycosides
Digoxin antibody
Dihydralazine
Dihydrocodeine when compounded with one or more other medicaments—
	(a)	in divided preparations containing not more than 100 mg of dihydrocodeine per dosage unit; or
	(b)	in undivided preparations with a concentration of not more than 2.5% of dihydrocodeine;
	except when included in Schedule 2 or 3
Dihydrostreptomycin, except when included in Schedule 6
Diisopropylamine dichloroacetate
Diltiazem
Dimenhydrinate, except when included in Schedule 2 or 3
Dimethindene, except when included in Schedule 3
Dimethisoquin, except when included in Schedule 2
Dimethoxanate
Dimethyl sulphoxide for therapeutic use, except—
	(a)	when included in Schedule 6; or
	(b)	in in vitro test kits
Dimetridazole
2,4-Dinitrochlorobenzene for therapeutic use
Dinitrocresols for therapeutic use
Dinitronaphthols for therapeutic use
Dinitrophenols for therapeutic use
Dinitrothymols for therapeutic use
Dinoprost
Diperodon
Diphemanil methylsulphate, except when included in Schedule 2
Diphenhydramine, except when included in Schedule 2 or 3
Diphenidol
Diphenoxylate in preparations containing, per dosage unit, 2.5 mg or less of diphenoxylate and a quantity of atropine sulphate equivalent to at least 1% of the dose of diphenoxylate
Diphenylpyraline, except when included in Schedule 2 or 3
Dipivefrin
Dipyridamole
Disophenol
Disopyramide
Distigmine
Disulfiram for therapeutic use
Dithiazanine, except when included in Schedule 6
Dobutamine
Domperidone
Dopamine
Dothiepin
Doxapram
Doxepin
Doxorubicin
Doxycycline
Doxylamine, except when included in Schedule 2 or 3
Droperidol
Drostanolone
Dydrogesterone
Econazole, except when included in Schedule 3 or 6
Edetic acid for human therapeutic use in preparations for injection or infusion
Emetine, except in preparations containing 0.2% or less of emetine
Enalapril
Enflurane for therapeutic use
Ephedrine, except—
	(a)	when included in Schedule 2 or 3;
	(b)	in preparations for topical use containing 1% or less of ephedrine; or
	(c)	for internal use for the relief of respiratory tract conditions only, when compounded with one or more other therapeutically active substances in liquid preparations containing 10 mg or less of ephedrine per recommended dose
Epicillin
Epirubicin
Ergometrine
Ergot
Erythromycin, except—
	(a)	when included in Schedule 6;
	(b)	in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances; or
	(c)	in milk replacers for calves and starter rations for pigs containing 100 mg/kg or less of antibiotic substances
Estramustine
Ethacrynic acid
Ethambutol
Ethamivan
Ethchlorvynol
Ether for use in anaesthesia
Ethinamate
Ethinyloestradiol
Ethoglucid
Ethoheptazine, except when included in Schedule 2
Ethopropazine
Ethosuximide
Ethotoin
Ethoxzolamide
Ethyl chloride for inhalation anaesthesia
Ethylmorphine when compounded with one or more other medicaments—
	(a)	in divided preparations containing not more than 100 mg of ethylmorphine per dosage unit; or
	(b)	in undivided preparations with a concentration of not more than 2.5% of ethylmorphine;
except when included in Schedule 2
Ethyloestrenol
Ethynodiol
Etidocaine
Etidronate, except in tooth pastes and gels containing 1% or less of etidronate
Etilefrin hydrochloride
Etoposide
Etretinate
Famotidine
Felodipine
Felypressin
Fencamfamin
Fenfluramine
Fenoprofen
Fenoterol, except when included in Schedule 3
Fenpipramide
Fenpiprane
Fenproporex
Fenprostalene for the treatment of animals
Flavophospholipol, except—
	(a)	when included in Schedule 6; or
	(b)	in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances
Flecainide
Flucloxacillin
Flucytosine
Flufenamic acid
Flumazanil
Flunisolide
Flunitrazepam
Flunixin meglumine for the treatment of animals
Fluorides in preparations for human ingestion, except when included in Schedule 2 or 3
Fluorouracil
Fluoxetine
Fluoxymesterone
Fluphenazine
Fluprostenol for the treatment of animals
Flurazepam
Fluroxene for inhalation anaesthesia
Fluspirilene
Follicle-stimulating hormone (animal)
Fosfestrol
Framycetin
Frusemide
Fusidic acid
Galanthamine
Gallamine
Gemeprost
Gentamicin
Glibenclamide
Glibornuride
Gliclazide
Glipizide
Glucagon
Glutethimide
Glyceryl trinintrate in preparations for injection
Glycopyrrolate
Glymidine
Gonadorelin
Gonadotrophins, except when separately specified in this Schedule or in Schedule 2
Goserelin acetate
Gramicidin
Griseofulvin
Growth hormone
Guaiphenesin, except when included in Schedule 2
Guanabenz
Guanacline
Guanethidine
Halcinonide
Haloperidol and other substances structurally derived from butyrophenone with ataractic properties, when used for therapeutic purposes, except when separately specified in this Schedule
Halothane for therapeutic use
Heparin for internal therapeutic use
Hetacillin
Hexachlorophane—
	(a)	in preparations for use on infants; or
	(b)	in other preparations, except when included in Schedule 2 or 6
Hexamethonium
Hexocyclium
Homatropine, except when included in Schedule 2
Hyaluronic acid in preparations for injection
Hydralazine
Hydrochlorothiazide
Hydrocyanic acid for therapeutic use
Hydroflumethiazide
Hydroquinone (other than its alkyl ethers separately specified in this Schedule) in preparations for human therapeutic or cosmetic use, except—
	(a)	when included in Schedule 2; or
	(b)	in hair preparations containing 1% or less of hydroquinone
Hydroxychloroquine
Hydroxyephedrine
Hydroxyprogesterone
Hydroxyurea
Hydroxyzine
Hygromycin, except—
	(a)	when included in Schedule 6; or
	(b)	in preparations in concentrations of 50 mg/kg or less of antibiotic substances
Hyoscine, except when included in Schedule 2
Hyoscyamine, except when included in Schedule 2
Hyoscyamus, except when included in Schedule 2
Hypothalamic releasing factors, except when separately specified in this Schedule
Ibufenac
Ibuprofen, except when included in Schedule 3
Idoxuridine, except when included in Schedule 3
Imipenem
Imipramine
Indapamide
Indomethacin
Inositol nicotinate for internal use
Interferon
Ion-exchange resins, anionic and cationic, for internal use in humans, except when separately specified in this Schedule
Iopamidol
Ipratropium
Iproniazid
Iron compounds in injectable preparations for human therapeutic use
Isoaminile
Isocarboxazid
Isoconazole, except when included in Schedule 3 or 6
Isoetharine
Isoflurane for therapeutic use
Isometheptene
Isoniazid
Isoprenaline
Isopropamide, except when included in Schedule 2
Isotretinoin
Isoxuprine
Ivermectin for the treatment of dogs
Kanamycin
Ketamine
Ketoconazole
Ketoprofen
Khellin
Kitasamycin, except—
	(a)	when included in Schedule 6; or
	(b)	in animal feeds for growth promotion containing 100 mg/kg or less of antibiotic substances
Labetalol
Latamoxef
Laudexium methylsulphate
Lead compounds for human therapeutic use
Lefetamine
Leptazol
Leuprorelin
Levallorphan
Levamisole—
	(a)	for human therapeutic use; or
	(b)	in preparations for the prevention or treatment of heartworm in dogs
Levodopa
Levonorgestrel
Lidoflazine
Lignocaine, except when included in Schedule 2
Lincomycin
Lindane for human therapeutic use, except when included in Schedule 2
Liothyronine sodium (triiodothyronine)
Lithium salts for therapeutic use, except in preparations containing 0.01% or less of lithium
Lobelia, except—
	(a)	when included in Schedule 2; or
	(b)	in preparations for smoking or burning
Lobeline, except—
	(a)	when included in Schedule 2; or
	(b)	in preparations for smoking or burning
Lomustine
Loperamide, except when included in Schedule 3
Lorazepam
Loxapine
Luteinising hormone—see also Gonadotrophins
Lymecycline
Mafenide, except when included in Schedule 6
Maldison for human therapeutic use, except when included in Schedule 2
Maprotiline
Mazindol
Mebeverine
Mebhydrolin
Mecamylamine
Meclofenoxate
Meclozine
Medazepam
Medroxyprogesterone
Mefenamic acid, except when included in Schedule 3
Mefenorex
Mefloquine
Mefruside
Megestrol
Melphalan
Mepacrine
Mepenzolate
Mephenesin
Mephentermine
Mepivacaine
Meprobamate
Mepyramine, except when included in Schedule 3
Mercaptopurine
Mercury for therapeutic use, except when included in Schedule 2 or 6
Mesalazine
Mesterolone
Mestranol
Metaraminol
Metergoline for the treatment of animals
Metformin
Methacycline
Methandienone
Methandriol
Methanthelinium
Methazolamide
Methdilazine, except when included in Schedule 3
Methenolone
Methicillin
Methimazole
Methixene
Methocarbamol
Methotrexate
Methoxsalen
Methoxyflurane for therapeutic use
Methsuximide
Methyclothiazide
Methylandrostanolone
Methyldopa
Methylpentynol and other substituted alkynes for internal use
Methyltestosterone
Methyprylone
Methysergide
Metoclopramide
Metolazone
Metoprolol
Metrizamide
Metronidazole including benzoyl metronidazole
Metyrapone
Mexiletine
Mezlocillin
Mianserin
Mibolerone
Miconazole, except when included in Schedule 2, 3 or 6
Midazolam
Minocycline
Minoxidil
Misoprostol
Mithramycin
Mitobronitol
Mitomycin
Mitozantrone
Monensin, except—
	(a)	when included in Schedule 6; or
	(b)	in animal feeds containing 33 mg/kg or less of antibiotic substances
Monobenzone and other alkyl ethers of hydroquinone for human therapeutic use or cosmetic use
Monoclonal antibodies for therapeutic use, except in diagnostic test kits
Moperone
Mupirocin
Mustine
Nadolol
Nalbuphine
Nalidixic acid, except when included in Schedule 6
Nalorphine
Naloxone
Nandrolone
Naproxen, except when included in Schedule 2
Narasin, except—
	(a)	when included in Schedule 6; or
	(b)	in animal feeds containing 100 mg/kg or less of antibiotic substances
Natamycin
Neomycin, except when included in Schedule 6
Neostigmine
Netilmicin
Nicocodine when compounded with one or more other medicaments—
	(a)	in divided preparations containing not more than 100 mg of nicocodine per dosage unit; or
	(b)	in undivided preparations with a concentration of not more than 2.5% of nicocodine
Nicodicodine when compounded with one or more other medicaments—
	(a)	in divided preparations containing not more than 100 mg of nicodicodine per dosage unit; or
	(b)	in undivided preparations with a concentration of not more than 2.5% of nicodicodine
Nicotine in chewing tablets containing 4 mg or less of nicotine per tablet for use as an aid in withdrawal from tobacco smoking, except when included in Schedule 3
Nicotinic acid for human therapeutic use, except—
	(a)	in preparations containing 50 mg or less of nicotinic acid per recommended daily dose; or
	(b)	nicotinamide
Nicotinyl alchohol for internal use
Nicoumalone for internal therapeutic use
Nifedipine
Nifenazone
Nikethamide
Niridazole
Nitrazepam
Nitrofuran and its derivatives for human therapeutic use, except when included in Schedule 3
Nitrous oxide for therapeutic use
Nizatadine
Nomifensine
Noradrenaline, excluding its derivatives
Norcodeine when compounded with one or more other medicaments—
	(a)	in divided preparations containing not more than 100 mg of norcodeine per dosage unit; or
	(b)	in undivided preparations with a concentration of not more than 2.5% of norcodeine
Norethandrolone
Norethisterone
Norfloxacin
Nortriptyline
Novobiocin, except when included in Schedule 6
Nystatin, except when included in Schedule 3
Octamylamine
Octatropine
Octreotide
Oestradiol, except when included in Schedule 6
Oestriol
Oestrone
Oleandomycin, except—
	(a)	when included in Schedule 6; or
	(b)	in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances
Olsalasine sodium
Omeprazole
Opipramol
Orciprenaline
Organophosphorus compounds with anticholinesterase activity for human therapeutic use, except—
	(a)	when included in Schedule 2; or
	(b)	when separately specified in this Schedule
Ornidazole
Ornipressin
Orphenadrine
Orthocaine
Orthopterin
Oxacillin
Oxandrolone
Oxazepam
Oxiconazole
Oxolamine
Oxpentifylline
Oxprenolol
Oxybuprocaine
Oxymesterone
Oxymetholone
Oxyphenbutazone
Oxyphencyclimine
Oxyphenonium
Oxytetracycline, except when included in Schedule 6
Oxytocin
Pamaquine
Pancuronium bromide
Papaverine for injection
Paracetamol when combined with aspirin, caffeine or salicylamide or any derivative of these substances
Paraldehyde
Paromomycin
Pemoline
Pempidine
Penicillamine
Pentamethonium
Penthienate
Pentobarbitone when packed and labelled for injection
Pentolinium
Perhexilene
Pericyazine
Perphenazine
Phenacemide
Phenacetin for therapeutic use
Phenazone, except when included in Schedule 2
Phenazopyridine
Phenelzine
Phenethicillin, except when included in Schedule 6
Phenformin
Phenglutarimide
Phenindione for internal therapeutic use
Pheniramine, except when included in Schedule 2 or 3
Phenoxybenzamine
Phenoxymethylpenicillin, except when included in Schedule 6
Phensuximide
Phentermine
Phenthimentonium
Phentolamine
Phenyapin
Phenylbutazone
Phenylephrine in preparations for human ophthalmic use containing 5% or more of phenylephrine
Phenylpropanolamine, except when included in Schedule 3
Phenyltoloxamine, except when included in Schedule 3
Phenytoin
Pholcodine when compounded with one or more other medicaments—
	(a)	in divided preparations containing not more than 100 mg of pholcodine per dosage unit; or
	(b)	in undivided preparations with a concentration of not more than 2.5% of pholcodine;
except when included in Schedule 2
Physostigmine
Picrotoxin
Pilocarpine, except in preparations containing 0.025% or less of pilocarpine
Pimozide
Pindolol
Pipenzolate
Piperacillin
Piperidolate
Pipobroman
Pipradrol
Pirenzepine
Piroxicam
Pituitary and its extracts and active principles or their synthetic substitutes, except when separately specified in this Schedule
Pizotifen
Podophyllotoxin for human therapeutic use, except when included in Schedule 2 or 3
Podophyllum resin (podophyllin) for human therapeutic use, except when included in Schedule 2 or 3
Polyestradiol
Polymethylene bistrimethyl ammonium compounds
Polymyxin
Polysulphated glycosaminoglycans in preparations for injection, except where otherwise specified in this Schedule
Potassium perchlorate for therapeutic use
Practolol
Pramoxine, except when included in Schedule 2
Prazepam
Praziquantel for human therapeutic use
Prazosin
Pregnenolone acetate, except in preparations for topical use
Prenylamine
Prilocaine
Primaquine
Primidone
Probenecid
Probucol
Procainamide
Procaine
Procarbazine
Prochlorperazine
Procyclidine, except when included in Schedule 2
Progesterone, except when included in Schedule 6
Proguanil
Prolintane
Promazine
Promethazine, except when included in Schedule 2 or 3
Propanidid
Propantheline, except when included in Schedule 2
Propofol
Propoxur for human therapeutic use
Propranolol
Propylhexedrine
Propylthiouracil
Propyphenazone
Proquazone
Prostaglandins, except where separately specified in this Schedule
Prostianol for the treatment of animals
Prothionamide
Protirelin (thyrotrophin releasing factor)
Protriptyline
Proxymetacaine
Pseudoephedrine in preparations for stimulant, appetite suppression or weight control purposes
Pyrazinamide
Pyridostigmine
Pyridoxine hydrochloride in preparations for human use containing more than 50 mg of pyridoxine per recommended daily dose, unless labelled—
“WARNING—THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG TIME”; or
“WARNING—THIS PRODUCT CONTAINS PYRIDOXINE HYDROCHLORIDE WHICH MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG TIME”
Pyrimethamine
Pyrovalerone
Quinethazone
Quinidine
Ranitidine
Rauwolfia serpentina
Ribavirin
Rifampicin
Rimiterol hydrobromide
Ritodrine
Rolitetracycline
Rosoxacin
Salbutamol, except when included in Schedule 3
Salicylamide when combined with aspirin, caffeine or paracetamol or any derivative of these substances
Salinomycin, except—
	(a)	when included in Schedule 6; or
	(b)	in animal feeds containing 60 mg/kg or less of antibiotic substances
Selenium for therapeutic use, except—
	(a)	when included in Schedule 5 or 6;
	(b)	as elemental selenium in pellets containing 50 mg/kg or less of selenium for the treatment of animals;
	(c)	in tablets, for the treatment of animals, each—
	(i)	weighing 2 g or more; and
	(ii)	containing 30 micrograms or less of selenium; or
	(d)	in animal feeds containing 0.1 g/tonne or less of selenium
Semisodium valproate
Sera for human therapeutic use
Sermorelin
Sex hormones and all substances having sex hormonal activity, except when separately specified in these Schedules
Silver sulphadiazine
Sisomycin
Sodium cellulose phosphate for human internal use
Sodium cromoglycate, except when included in Schedule 2
Sodium nitroprusside for human therapeutic use
Sodium pentosan polysulphate for the treatment of animals
Sodium valproate
Sontoquine
Sotalol
Sparteine
Spectinomycin
Spiramycin, except—
	(a)	when included in Schedule 6; or
	(b)	in animal feeds for growth promotion in pigs or poultry containing 50 mg/kg or less of antibiotic substances
Spironolactone
Sputolysin—see trans-4-((3,5-Dibromo-2-hydroxybenzyl)-amino) cyclohexanol hydrochloride monohydrate
Stanolone
Stanozolol
Stilboestrol
Stramonium, except—
	(a)	when included in Schedule 2; or 
	(b)	in preparations for smoking or burning
Streptomycin, except when included in Schedule 6
Strophanthus and its glycosides
Strychnine in preparations containing 1.5% or less of strychnine for the treatment of animals
Sulfadoxine
Sulphametrole
Sulindac
Sulphatroxazole for the treatment of animals
Sulphinpyrazone
Sulphomyxin
Sulphonal and alkyl sulphonals
Sulphonamides, except—
	(a)	when included in Schedule 6;
	(b)	when separately specified in this Schedule;
	(c)	oryzalin;
	(d)	sulphaquinoxaline in animal feeds containing 200 mg/kg or less of sulphaquinoxaline; or
	(e)	sulphaquinoxaline when incorporated in baits for the destruction of vermin
Sulthiame
Suxamethonium salts
Tacrine
Tamoxifen
Temazepam
Teniposide
Tenoxicam
Terbutaline, except when included in Schedule 3
Terfenadine, except when included in Schedule 3
Teropterin
Testosterone, except when included in Schedule 6
Tetrabenazine
Tetracosactrin
Tetracycline, except when included in Schedule 6
Thalidomide
Thenyldiamine, except when included in Schedule 2 or 3
Theophylline, except when included in Schedule 3
Thiacetarsamide in preparations for the prevention or treatment of heart worm in dogs
Thiacetazone
Thiambutosine
Thiazosulphone
Thiethylperazine
Thioguanine
Thiopropazate
Thioridazine
Thiotepa
Thiothixene
Thiouracil
Thiourea for therapeutic use
Thyroid and its extracts and active principles, except when separately specified in this Schedule
Thyrotrophin (TSH)
Thyroxine sodium
Tiamulin, except—
	(a)	when included in Schedule 6; or
	(b)	in prepared animal feeds
Ticarcillin
Tiemonium
Tigloidine
Tiletamine for the treatment of animals
Timolol
Tinidazole
Tioconazole, except when included in Schedule 3
Tipepidine
Tobramycin
Tocainide
Tolazamide
Tolazoline for internal use
Tolbutamide
Tolpropamine
Toxoids for human therapeutic use
Tranexamic acid
Tranylcypromine
Tretamine
Triamterene
Triaziquone
Triazolam
Trichloroethylene for therapeutic use
Triclofos
Tricyclamol
Tridihexethyl
Trifluoperazine
Trifluperidol
Trimeprazine, except when included in Schedule 2 or 3
Trimetaphan
Trimethoprim
Trimipramine
Trimustine
Trioxysalen
Tripelennamine
Triprolidine, except when included in Schedule 2 or 3
Tropicamide
Troxidone
Tubocurarine
Tulobuterol
Tylosin, except—
	(a)	when included in Schedule 6;
	(b)	in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances; or
	(c)	in milk replacers for calves or starter rations for pigs containing 100 mg/kg or less of antibiotic substances
Urethane, excluding its derivatives, for therapeutic use
Urofollitrophin (human follicle-stimulating hormone)
Vaccines for human therapeutic use
Vaccines, veterinary live virus, except—
	(a)	poultry vaccines;
	(b)	pigeon pox vaccine; or
	(c)	scabby mouth vaccine
Valnoctamide
Vancomycin
Vasopressin
Vecuronium bromide
Verapamil
Veratrum
Vidarabine
Vinblastine
Vincristine
Vindesine
Viprynium
Virginiamycin, except—
	(a)	when included in Schedule 6; or
	(b)	in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances
Visnadine
Vitamin A for human therapeutic use, except in preparations containing 10 000 I.U. or less of vitamin A per recommended daily dosage
Vitamin D for human therapeutic use, except in preparations containing 25 micrograms or less of vitamin D per recommended daily dosage
Warfarin for internal therapeutic use

Xanthinol nicotinate
Xylazine
Yohimbine
Zeranol, except when included in Schedule 6
Zidovudine
Zinc compounds for human internal use, except—
	(a)	in preparations with a recommended daily dose of 25 mg or less of zinc; or
	(b)	in preparations with a recommended daily dose of more than 25 mg but not more than 50 mg of zinc when the pack is labelled—
		“WARNING—MAY BE DANGEROUS IF TAKEN IN LARGE AMOUNTS OR FOR A LONG PERIOD”; or
		“WARNING—CONTAINS ZINC, WHICH MAY BE DANGEROUS IF TAKEN IN LARGE AMOUNTS OR FOR A LONG PERIOD”
Zolazepam for the treatment of animals

	SCHEDULE 5	Section 3
Acetic acid (excluding its salts and derivatives) in preparations containing more than 30% of acetic acid, except—
	(a)	when included in Schedule 2 or 6; or
	(b)	for therapeutic use
Acetone, except—
	(a)	in preparations containing 25% or less of acetone; or
	(b)	in containers having a capacity of more than 25 litres which are labelled “WARNING” and state the proportion of acetone
Acetophenone—see Phenyl methyl ketone
Aklomide
Alkaline salts, being the carbonate, orthosilicate, metasilicate or tribasic phosphate salts of sodium or potassium, in any combination, except—
	(a)	in preparations containing 10% or less of combined substances;
	(b)	in solid preparations whose pH in 10 g/L aqueous solution is 11.5 or less; or
	(c)	in liquid preparations having a pH of 11.5 or less
Alloxydim
Ametryn
Amines for use as curing agents for epoxy resins, except when separately specified in these Schedules
Amitrole
Ammonia (exluding its salts and derivatives other than ammonium hydroxide) in preparations containing 5% or less of ammonia, except—
	(a)	in preparations for human internal therapeutic use;
	(b)	in preparations for inhalation when absorbed in an inert solid material; or
	(c)	in preparations containing 0.5% or less of ammonia
Ammonium thiocyanate, except in preparations containing 10% or less of ammonium thiocyanate
Anhydrides, organic, for use as curing agents for epoxy resins, except when separately specified in these Schedules
Arsenic organic compounds in herbicides or defoliant preparations containing 3% or less of arsenic, except when separately specified in this Schedule
Azamethiphos
Barium silicofluoride when coated on paper in an amount not exceeding 8 mg per sq. cm.
Benalaxyl
Bendiocarb in preparations containing 2% or less of bendiocarb
Bentazone
Benzoyl peroxide, except—
	(a)	when included in Schedule 2, 3 or 4; or
	(b)	in preparations containing 2% or less of benzoyl peroxide
BHC (excluding lindane) in preparations containing 10% or less of BHC
Bioallethrin (including sinbioallethrin), except in preparations containing 10% or less of bioallethrin
Bioresmethrin, except in preparations containing 10% or less of bioresmethrin
Boric acid (excluding its salts) and borax, except—
	(a)	when included in Schedule 4;
	(b)	in preparations, other than insect baits, containing 1% or less of boron; or
	(c)	in hand cleaning preparations
Buthidazole
Butoxycarboxim in solid preparations containing 10% or less of butoxycarboxim
Cadmium sulphide in preparations containing 2.5% or less of cadmium sulphide for human therapeutic use
Calcium hypochlorite, except in preparations containing 4% or less of available chlorine
Camphor, except—
	(a)	when included in Schedule 4;
	(b)	when enclosed in an inhaler device which prevents ingestion of its contents; or
	(c)	in preparations containing 10% or less of camphor
Carbaryl—
	(a)	in preparations containing 10% or less of carbaryl, except when included in Schedule 2 or 4; or
	(b)	when impregnated into plastic resin material containing 20% or less of carbaryl
Chlorfenac
Chlorfenson
Chlorinated lime, except in preparations containing 4% or less of available chlorine
Chlorinating compounds, except—
	(a)	solid preparations containing 4% or less of available chlorine;
	(b)	liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled in letters not less than 2mm in height—
		“WARNING—ENSURE ADEQUATE VENTILATION WHEN USING.  VAPOUR MAY BE HARMFUL.  MAY GIVE OFF DANGEROUS GAS IF MIXED WITH OTHER PRODUCTS”; or
	(c)	liquid preparations containing less than 2% of available chlorine
Chlornidine
Chlorocresol, except in preparations containing 3% or less of chlorocresol
Chlorpyrifos in preparations containing 5% or less of chlorpyrifos
Chlorsulfuron
Clanobutin for the treatment of animals, except when included in Schedule 4
Climbazole in preparations containing 40% or less of climbazole, except in preparations containing 2% or less of climbazole
Clofentezine
Clopyralid
Copper sulphate, except—
	(a)	in preparations for internal use; or
	(b)	in other preparations containing 5% or less of copper sulphate
4-CPA
Cuprimyxin for the treatment of animals
Cyanatryn
Cyanoacrylic esters in contact adhesives, except when labelled—
“KEEP OUT OF REACH OF CHILDREN.  AVOID CONTACT WITH SKIN AND EYES AND AVOID BREATHING VAPOUR.  BONDS ON CONTACT.  SHOULD FINGERS STICK TOGETHER APPLY A SOLVENT SUCH AS ACETONE TO CONTACT AREAS THEN WASH OFF WITH WATER.  DO NOT USE SOLVENTS NEAR EYES OR OPEN WOUNDS.  IN CASE OF EYE CONTACT IMMEDIATELY FLUSH WITH WATER.”
Cyanuric acid, excluding its salts and derivatives
Cyclohexanone peroxide
Cycloprothrin, except in preparations containing 10% or less of cycloprothrin
Cyfluthrin—
	(a)	in wettable powders containing 10% or less of cyfluthrin; or
	(b)	in emulsifiable concentrates containing 2% or less of cyfluthrin
Cypermethrin in preparations containing 10% or less of cypermethrin
2,4-D
2,4-DB
DDT in preparations containing 10% or less of DDT, except dicophane when included in Schedule 2
2,4-DES
Deltamethrin in aqueous formulations containing 1% or less of deltamethrin, when no organic solvent, other than a glycol, is present
N,N-Diallyldichloroacetamide, except in preparations containing 10% or less of N,N-diallyldichloroacetamide
Diazinon in dust preparations containing 2% or less of diazinon
Dicamba
Dichlofluanid
Dichlone
Dichloroisocyanurates, except in preparations containing 4% or less of available chlorine
Dichlorophen for the treatment of animals
2’,4’-Dichloro-2-(3-pyridyl)-acetophenone-O-methyloxime (pyrifenox)
Dichlorvos—
	(a)	when impregnated in plastic resin strip material containing 20% or less of dichlorvos;
	(b)	in sustained release resin pellets containing 20% or less of dichlorvos for the treatment of animals; or
	(c)	in pressurised spray packs containing 10 grams or less of dichlorvos
Diclobutrazol
Dicloran
Dicofol
Dicophane—see DDT
Diethyltoluamide, except in preparations containing 20% or less of diethyltoluamide when labelled—
“WARNING—THIS PRODUCT CONTAINS DIETHYLTOLUAMIDE, WHICH MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD”
Dimethirimol
Dimethylformamide in preparations containing 10% or less of dimethylformamide, except in containers having a capacity of more than 25 litres which are labelled “WARNING” and state the proportion of dimethylformamide
Diniconazole
Diphenamid
Dodine
DSMA in herbicides or defoliant preparations containing 3% or less of arsenic
Enilconazole
Epoxy resins, liquid
EPTC
Ethephon, excluding its salts and derivatives
Ether in preparations containing more than 10% of ether for use in internal combustion engines
Ethofumesate
Ethoxyquin, except in preparations containing 10% or less of ethoxyquin
Ethylene glycol when packed and labelled as a boiling point or freezing point modifier containing not less than 10 mg/kg of denatonium benzoate as a bittering agent
Etridiazole
Fenarimol
Fenoprop
Fenoxaprop-ethyl
Fenson
Fenthion in preparations containing 25% or less of fenthion when packed in single-use containers having a capacity of 2 ml or less
Flamprop-methyl
Fluchloralin
Flumethrin in oil based preparations containing 1% or less of flumethrin
Fluorides (including silicofluorides) in preparations containing 0.5% or less of fluoride ion, except—
	(a)	in dentifrices containing 1000 mg/kg or less of fluoride ion; or
	(b)	in preparations containing 15 mg/kg or less of fluoride ion
Fluvalinate in aqueous preparations containing 25% or less of fluvalinate
Formic acid (excluding its salts and derivatives), except in preparations containing 0.5% or less of formic acid
Fospirate when impregnated in plastic resin strip material containing 20% or less of fospirate
Furalaxyl
Glufosinate-ammonium
Glutaraldehyde in preparations containing 5% or less of glutaraldehyde, except when included in Schedule 2
Glyphosate
Hexaconazole, except in preparations containing 5% or less of hexaconazole
Hexazinone
Hydramethylnone in solid baits containing 2% or less of hydramethylnone in welded plastic labyrinths
Hydrocarbons, liquid, (including kerosene, mineral turpentine, white petroleum spirit, toluene, xylene and light mineral and paraffin oils (but excluding their derivatives)) distilling under 300oC, except—
	(a)	toluene and xylene when included in Schedule 6;
	(b)	in containers having a capacity of more than 25 litres which are labelled “WARNING” and state the proportion of liquid hydrocarbons;
	(c)	in solid or semi-solid preparations;
	(d)	in preparations containing 25% or less of liquid hydrocarbons;
	(e)	in preparations packed in pressurised spray packs; or
	(f)	in adhesives packed in containers each containing 50 grams or less of adhesive
Hydrochloric acid (excluding its salts and derivatives) in preparations containing 10% or less of hydrochloric acid (HC1), except—
	(a)	in preparations containing 0.5% or less of hydrochloric acid (HCl); or
	(b)	for therapeutic use
Hydrofluoric acid (including hydrosilicofluoric acid but excluding their salts and derivatives) in preparations containing the equivalent of 0.5% or less of hydrogen fluoride
Hydrogen peroxide (excluding its salts and derivatives), except in preparations containing 6% (20 vol) or less of hydrogen peroxide
Imazalil
Iodocarb, except in aqueous preparations containing 10% or less of iodocarb
Isophorone
Kerosene—see Hydrocarbons
Lead compounds in preparations for use as hair cosmetics
Levamisole in preparations containing 15% or less of levamisole for the treatment of animals, except when included in Schedule 4
Lindane in preparations containing 10% or less of lindane, except when included in Schedule 2 or 4
Maldison in preparations containing 10% or less of maldison, except—
	(a)	when included in Schedule 2 or 4; or
	(b)	in dust preparations containing 2% or less of maldison
Mancozeb
Maneb
MCPA
MCPB
Mecoprop
Mepiquat
Metalaxyl
Metaldehyde in preparations containing 2% or less of metaldehyde
Methabenzthiazuron
Methanol (excluding its derivatives) in preparations containing 10% cent or less of methanol, except—
	(a)	in preparations containing 2% or less of methanol; or
	(b)	in containers having a capacity of more than 25 litres which are labelled “WARNING” and state the proportion of methanol
Methiocarb in pelleted preparations containing 2% or less of methiocarb
Methoxychlor
Methylated spirit (being ethanol denatured with denatonium benzoate, methyl isobutyl ketone and fluorescein) excluding its preparations and admixtures, except in containers having a capacity of more than 5 litres
Methylene chloride, except in pressurised spray packs other than when packed and labelled as degreasers, decarbonisers or paint strippers that contain more than 10% of methylene chloride
Methyl ethyl ketone, except—
	(a)	in preparations containing 25% or less of methyl ethyl ketone; or
	(b)	in containers having a capacity of more than 25 litres which are labelled “WARNING” and state the proportion of methyl ethyl ketone
Methyl ethyl ketone peroxide
Methyl isoamyl ketone, except—
	(a)	in preparations containing 25% or less of methyl isoamyl ketone; or
	(b)	in containers having a capacity of more than 25 litres which are labelled “WARNING” and state the proportion of methyl isoamyl ketone
Methyl isobutyl ketone, except—
	(a)	in preparations containing 25% or less of methyl isobutyl ketone; or
	(b)	in containers having a capacity of more than 25 litres which are labelled “WARNING” and state the proportion of methyl isobutyl ketone
Methyl salicylate in liquid preparations containing 25% or more of methyl salicylate, except when included in Schedule 6
N-(3-Methyl-4-thiazolin-2-ylidene)-2,4-xylidene (cymiazole)
Metiram
Metolachlor
Metribuzin
Mezineb
Mineral turpentine—see Hydrocarbons
MSMA in herbicides or defoliant preparations containing 3% or less of arsenic
Myclobutanil
NAA, except in preparations containing 25% or less of NAA
Naled when impregnated in plastic resin strip material containing 20% or less of naled
Naphthalene
Naphthaleneacetic acid—see NAA
Naptalam
Nitric acid (excluding its salts and derivatives) in preparations containing 10% or less of nitric acid, except preparations containing 0.5% or less of nitric acid
Norbormide
Ofurace
Oxadixyl
Oxycarboxin
Oxythioquinox
Paclobutrazol
Paradichlorobenzene
Pebulate
Penconazole
Pendimethalin
Peracetic acid in concentrations of 10% or less of peracetic acid
Petrol, except—
	(a)	in preparations containing 25% or less of petrol; or
	(b)	in containers having a capacity of more than 25 litres which are labelled “WARNING” and state the proportion of petrol
Phenisopham
Phenyl methyl ketone, except—
	(a)	in preparations containing 25% or less of phenyl methyl ketone; or
	(b)	in containers having a capacity of more than 25 litres which are labelled “WARNING” and state the proportion of phenyl methyl ketone
ortho-Phenylphenol, except in preparations containting 5% or less of ortho-phenylphenol
Phosphonic acid (excluding its salts and derivatives), except in preparations containing 10% or less of phosphonic acid
Phosphoric acid (excluding its salts and derivatives), except—
	(a)	when packed in containers having a capacity of not less than 10 litres and labelled “CORROSIVE” in bold face sanserif capital letters of a height of not less than 1 cm;
	(b)	in preparations containing 350 g/litre or less of phosphoric acid;
	(c)	in solid and semi-solid preparations; or
	(d)	in professional dental kits
Pirimicarb in preparations containing 0.5% or less of pirimicarb
Poly (hexamethylene biguanide), except in preparations containing 5% or less of poly (hexamethylene biguanide)
Potassium chlorate, except—
	(a)	when included in Schedule 2; or
	(b)	in preparations containing 10% or less of potassium chlorate
Potassium hydroxide (excluding its salts and derivatives) in preparations containing 5% or less of potassium hydroxide, except in preparations containing 0.5% or less of potassium hydroxide
Potassium metabisulphite when packed for domestic use, except in preparations containing 10% or less of potassium metabisulphite
Potassium sulphide in preparations for metal treatment in containers each containing 50 g or less of potassium sulphide
Prometryn
Propamocarb
Propanil
Propiconazole in preparations containing 20% or less of propiconazole
Propionic acid (excluding its salts and derivatives) in preparations containing 80% or less of propionic acid, except—
	(a)	in preparations containing 30% or less of propionic acid; or
	(b)	for therapeutic use
Propoxur—
	(a)	in dust preparations containing 3% or less of propoxur;
	(b)	in granular sugar-based fly baits containing 1% or less of propoxur, where the preparation also contains a dark colouring agent and a separate bittering agent;
	(c)	in aerosol packs containing 10 g or less of propoxur; or
	(d)	in printed paper sheets for pest control containing 0.5% or less of propoxur and in any case not more than 100 mg of propoxur per sheet
Pyrethrins, naturally occurring, being pyrethrolone, cinerolone of jasmolone esters of chrysanthemic or pyrethric acids, except in preparations containing 10% or less of such substances
Quaternary ammonium compounds, except—
	(a)	when separately specified in these Schedules; or
	(b)	in preparations containing 10% or less of quaternary ammonium compounds
Quintozene
Salicylanilide
Selenium sulphide in preparations for topical therapeutic use containing 2.5% or less of selenium sulphide
Sethoxydim
Sodium chlorate, except in preparations containing 10% or less of sodium chlorate 
Sodium hydrogen sulphate, except in preparations containing 10% or less of sodium hydrogen sulphate
Sodium hydroxide (excluding its salts and derivatives) in preparations containing 5% or less of sodium hydroxide, except in liquid preparations having a pH of 11.5 or less
Sodium hypochlorite, except in preparations containing 4% or less of available chlorine
Sodium metabisulphite when packed for domestic use, except in preparations containing 10% or less of sodium metabisulphite
Sodium nitrite, except—
	(a)	when included in Schedule 2; or
	(b)	in preparations containing 1% or less of sodium nitrite
Sodium sulphide—
	(a)	in preparations for metal treatment in containers each containing 50 g or less of sodium sulphide; or
	(b)	in preparations for use as insect lures
Styrene (excluding its derivatives), except in containers having a capacity of more than 25 litres which are labelled “WARNING” and state the proportion of styrene
Sulfometuron-methyl
Sulphamic acid, except in preparations containing 10% or less of sulphamic acid 2,3,6-TBA
TCA— see Trichloroacetic acid
TDE (1,1-dichloro-2,2-bis(4-chlorophenyl)ethane) in preparations containing 10% or less of TDE
Temephos—
	(a)	in liquid preparations containing 10% or less of temephos; or
	(b)	in powders containing 2% or less of temephos
Terbutryn
Tetrachloroethylene in preparations containing 5% or less of tetrachloroethylene, except—
	(a)	when prepared for therapeutic use;
	(b)	when absorbed into an inert solid; or
	(c)	in containers having a capacity of more than 25 litres which are labelled “WARNING” and state the proportion of tetrachloroethylene
Tetrachlorvinphos, except in animal feed containing 0.2% or less of tetrachlorvinphos
Tetramethrin (R,cis):(R,trans)=20:80, except in pressurised spray packs
Thifensulfuron
Thiobencarb
Tiocarbazil
Tolclofos-methyl
Tralkoxydim
Triadimefon in wettable powders containing 25% or less of triadimefon
Triadimenol
Tri-allate
Trichloroacetic acid, alkali salts of
1,1,1-Trichloroethane, except—
	(a)	in preparations packed in pressurised spray packs other than for therapeutic use;
	(b)	in preparations containing 25% or less of 1,1,1-trichloroethane;
	(c)	in preparations, other than writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 ml or less;
	(d)	in writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 ml or less labelled—
	(i)	“Trichloroethane” in letters not less than 1 mm in height and in distinct contrast to the background; and
	(ii)	“WARNING—DO NOT DELIBERATELY SNIFF THIS PRODUCT.  SNIFFING MIGHT HARM OR KILL YOU”, in bold sanserif capital letters not less than 1 mm in height and in a distinct contrast to the background; or
	(e)	in containers having a capacity of more than 25 litres which are labelled “WARNING” and state the proportion of 1,1,1-trichloroethane
Trichloroisocyanuric acid in compressed block form for use in swimming pools or toilet cisterns
Tridiphane
Trietazine
Triflumizole
Triflumuron
Turpentine oil, except—
	(a)	in preparations containing 25% or less of turpentine oil; or
	(b)	in containers having a capacity of more than 25 litres which are labelled “WARNING” and state the proportion of turpentine oil
Vernolate
Warfarin in rodent baits containing 0.1% or less of warfarin
Zineb
Ziram

	SCHEDULE 6	Section 3
Acephate
Acetic acid (excluding its salts and derivatives) and preparations containing more than 80% of acetic acid, except when included in Schedule 2
Acetic anhydride, excluding its derivatives
Acifluorfen
Albendazole in preparations for the treatment of animals
Aldrin
Amidithion
2-Amino-butane
Aminocarb in preparations containing 25% or less of aminocarb
Amitraz
Ammonia (excluding its salts and derivatives other than ammonium hydroxide), except—
	(a)	when included in Schedule 5;
	(b)	in preparations for human internal therapeutic use;
	(c)	in preparations for inhalation when absorbed in an inert solid material; or
	(d)	in preparations containing 0.5% or less of ammonia
Aniline (excluding its salts and derivatives), except in preparations containing 1% or less of aniline
Antimony compounds, except—
	(a)	when included in Schedule 4;
	(b)	antimony chloride in polishes; or
	(c)	antimony titanate pigments in paint
Arecoline
Arsenic—
	(a)	in ant poisons containing 0.4% or less of arsenic;
	(b)	organic compounds of arsenic in herbicides or defoliant preparations, except when included in Schedule 5;
	(c)	in animal feed premixes containing 4% or less of arsenic;
	(d)	in preparations for the treatment of animals, except thiacetarsamide when included in Schedule 4; or
	(e)	in paints containing more than 0.1% of arsenic when calculated on the basis of the non-volatile content of the paint;
except when separately specified in this Schedule
Asprin for the treatment of animals, except when included in Schedule 4
Avermectin B1 in preparations containing 1% or less of avermectin B1, for the treatment of animals, when supplied in sealed containers for use in automatic injection equipment
Azaconazole, except in preparations containing 1% or less of azaconazole
Azobenzene
Bacitracin in animal feed premixes for growth promotion containing 2% or less of antibiotic substances
Barium salts, except—
	(a)	when included in Schedule 5;
	(b)	barium sulphate; or
	(c)	barium metaborate in paint
Bendiocarb—
	(a)	in wettable powders containing 80% or less of bendiocarb, when packed in containers or primary packs containing not less than 100 g of bendiocarb;
	(b)	in wettable powders containing 20% or less of bendiocarb and not less than 0.002% of denatonium benzoate, when packed in containers or primary packs containing not less than 48 g of bendiocarb and labelled for use as a fly control preparation; or
	(c)	in insoluble granular preparations containing 5% or less of bendiocarb;
except when included in Schedule 5
Benomyl
Benquinox
Bensulide
5-Benzylfur-3-ylmethyl (1’R,3’S.E)-2’,2’-dimethyl-3’-(2-oxo-2,3,4,5-tetrahydro-3-thienylidenemethyl)-cyclopropane carboxylate
Benzylpenicillin (including procaine penicillin) in preparations for intramammary infusion in animals containing not more than 100 000 I.U. of benzylpenicillin or procaine penicillin per dose, when packed in an applicator device specially designed for intramammary infusion and suitably coloured with no less than 25 mg per dose of Brilliant Blue FCF so that the visual end point excludes 95% of excreted antibiotic
Beryllium
BHC (excluding lindane), except when included in Schedule 5
Bithionol for treatment of animals
Brodifacoum in preparations containing 0.25% or less of brodifacoum
Bromadiolone in preparations containing 0.25% or less of bromadiolone
Bromethalin in rodent baits containing 100 mg/kg or less of bromethalin
Bromoform, exept when included in Schedule 4
Bromophos
Bromophos-ethyl
Bromoxynil
Brotianide
Bunamidine
Butacarb
Butoxycarboxim, exept when included in Schedule 5
2-Butoxy-2’-thiocyano-diethyl ether
Butynorate
Cacodylic acid in animal feed premixes containing 4% or less of arsenic
Cadmium compounds, except when included in Schedule 5
Cajuput oil, except in oils or preparations containing 25% or less of cineole
Calciferol in rodent baits containing 1 g/kg or less of calciferol
Cambendazole
Carbaryl, except when included in Schedule 2, 4 or 5
Carbendazim
Carbon disulphide
a-Chloralose—see Chloralose
Chloralose (a-chloralose) when packed and labelled for use as a pesticide
Chlordane
Chlorfenethol
Chlormequat
N-[5-Chloro-4-[(4-chlorophenyl)-cyanomethyl]-2-methylphenyl]-2-hydroxy-3, 5-diiodobenzamide
Chloroform, except—
	(a)	when included in Schedule 2 or 4; or
	(b)	in preparations containing 10% or less of chloroform
a-Chlorohydrin
Chlorophacinone
Chloropicrin in preparations containing 5% or less of chloropicrin
Chlorothalonil
Chlorpyrifos, except when included in Schedule 5
Chlorpyrifos-methyl
Chlortetracycline in preparations—
	(a)	for topical application to animals for ocular use only; or
	(b)	for intramammary infusion in animals containing not more than 100 000 I.U. of chlortetracycline per dose, when packed in an applicator device specially designed for intramammary infusion and suitably coloured with no less than 25 mg per dose of Brilliant Blue FCF so that the visual end point excludes 95% of excreted antibiotic
Chlorthiamid
Cholecalciferol in rodent baits containing 1 g/kg or less or cholecalciferol
Chromates (including dichromates), except chromates of barium, potassium, sodium, strontium, zinc or ammonia, in paint containing 5% or less of chromium, calculated on the non-volatile content of the paint
Chromium trioxide, excluding its salts and derivatives
Cineole, except in oils or preparations containing 25% or less of cineole
Climbazole, except—
	(a)	when included in Schedule 5; or
	(b)	in preparations containing 2% or less of climbazole
Clotrimazole for external treatment of animals
Coumaphos in preparations containing 5% or less of coumaphos
Coumatetralyl
Creosote, except—
	(a)	when included in Schedule 2; or
	(b)	in preparations containing 3% or less of phenols and homologues of phenol boiling below 220°C
Crotoxyphos
Crufomate
Cyanamide
Cyanazine
Cyfluthrin, except—
	(a)	when included in Schedule 5; or
	(b)	in pressurised spray packs  containing 1% or less of cyfluthrin
Cyometrinil
Cypermethrin, except when included in Schedule 5
Cythioate
Dazomet
DDT and its preparations, except—
	(a)	when included in Schedule 5; or
	(b)	dicophane included in Schedule 2
Demeton-O-methyl in preparations containing 10% or less of demeton-O-methyl, or of demeton-O-methyl and demeton-S-methyl
Demeton-S-methyl in preparations containing 10% or less of demeton-S-methyl, or of demeton-S-methyl and demeton-O-methyl
Diazinon, except when included in Schedule 5
trans-4-((3,5-Dibromo-2-hydroxybenzyl)-amino) cyclohexanol hydrochloride monohydrate (sputolysin) in oral preparations for the treatment of animals
Dichlofenthion
ortho-Dichlorobenzene
Dichloroethyl ether
Dichlorophen, except when included in Schedule 5
1,2-Dichloropropane
Dichlorvos in preparations containing 50% or less of dichlorvos, except when included in Schedule 5
Diclofop-methyl
Dicophane—see DDT
Dieldrin
Difenacoum in preparations containing 0.25% or less of difenacoum
Difenzoquat
Dihydrostreptomycin in preparations for intramammary infusion in animals containing not more than 100 000 I.U. of dihydrostreptomycin per dose, when packed in an applicator device specially designed for intramammary infusion and suitably coloured with no less 	than 25 mg per dose of Brilliant Blue FCF so that the visual end point excludes 95% of excreted antibiotic
Dimethipin
Dimethoate
1,3-Di(methoxycarbonyl)-1-propen-2-yl-dimethyl phosphate in preparations containing 25% or less of 1,3-di(methoxycarbonyl)-1-propen-2-yl-dimethyl phosphate
Dimethylformamide, except—
	(a)	when included in Schedule 5; or
	(b)	in containers having a capacity of more than 25 litres which are labelled “POISON” and state the proportion of dimethylformamide
Dimethyl sulphoxide—
	(a)	when not for therapeutric use; or
	(b)	for the treatment of animals—
	(i)	when combined with no other therapeutic substance; or
	(ii)	in preparations containing copper salicylate as the only other therapeutic substance
Dinitrocresols and their homologues, in preparations containing 5% or less of such compounds, except—
	(a)	when included in Schedule 4; or
	(b) 	when separately specified in this Schedule
Dinitrophenols and their homologues, in preparations containing 5% or less of such compounds, except—
	(a)	when included in Schedule 4; or
	(b)	when separately specified in this Schedule
Dinocap
Dioxacarb
Dioxane
Diphacinone
Diquat
Disulfiram, except when included in Schedule 4
Disulfoton in granular preparations containing 5% or less of disulfoton
Dithianon
Dithiazanine in preparations containing 2% or less of dithiazanine, for the treatment of animals
Dithiocarbamates when prepared for agricultural, horticultural or pastoral purposes, except when separately specified in this Schedule or in Schedule 5
Diuredosan
DSMA in herbicides or defoliant preparations, except when included in Schedule 5
Econazole for the external treatment of animals
Endosulfan
Endothal in preparations containing 20% or less of endothal
Erythromycin—
	(a)	in preparations for intramammary infusion in animals containing not more than 100 000 I.U. of erythromycin per dose, when packed in an applicator device specially designed for intramammary infusion and suitably coloured with no less than 25 mg per dose of Brilliant Blue FCF so that the visual end point excludes 95% of excreted antibiotic; or
	(b)	in animal feed premixes for growth promotion containing 2% or less of antibiotic substances
Esfenvalerate
Ether, except—
	(a)	when included in Schedule 2, 4 or 5; or
	(b)	in preparations containing 10% or less of ether 
Ethiofencarb
Ethoate-methyl
Ethoprophos in granular formulations containing 10% or less of ethoprophos and 2% of linseed oil
Ethyl bromide
Ethyl-2-[4-(6-chloro-2-quinoxalyloxy)phenoxy] propionate (quizalofop ethyl)
Ethylene chlorohydrin
Ethylene dichloride
Ethylene glycol when packed and labelled as a boiling point or freezing point modifier, except when included in Schedule 5
Ethylene glycol monoalkyl ethers and their acetates, except—
	(a)	in preparations containing 10% or less of such substances; or
	(b)	in containers having a capacity of 25 litres or more which are labelled “POISON”, the name and quantity of the ether, the name of the manufacturer or the trade mark and the statement “Avoid contact with skin and eyes and avoid breathing the vapour”
Etrimfos
Eucalyptus oil, except in preparations containing 25% or less of eucalyptus oil
Famphur in preparations containing 20% or less of famphur
Fenaminosulf in preparations containing 10% or less of fenaminosulf when labelled and packed as dry seed dressings
Fenamiphos in granular preparations containing 5% or less of fenamiphos
Fenazaflor
Fenbutatin-oxide
Fenchlophos
Fenitrothion
Fenoxacarim in preparations for the treatment of carpets during manufacture
Fenthion, except when included in Schedule 5
Fenvalerate
Ferbam
Flavophospholipol in animal feed premixes for growth promotion containing 2% or less of antibiotic substances
Fluazifop-butyl
Fluazifop-p-butyl
Flucofuron in preparations for the treatment of carpets during manufacture
Flumethrin, except when included in Schedule 5
Fluorides (including silicofluorides), except—
	(a)	when included in Schedule 2, 3, 4 or 5;
	(b)	in preparations containing 3% or less of sodium fluoride or sodium silicofluoride as preservative;
	(c)	in pesticide preparations containing 3.2% or less of ammonium silicofluoride;
	(d)	in dentifrices containing 1000 mg/kg or less of fluoride ion; or
	(e)	in preparations containing 15 mg/kg or less of fluoride ion
Flusilazol
Flutriafol, except in fertilizers containing 0.5% or less of flutriafol
Fluvalinate, except when included in Schedule 5
Formaldehyde (excluding its derivatives other than paraformaldehyde), except in preparations containing 5% or less of formaldehyde
Formathion
Fospirate, except when included in Schedule 5
Fumagillin
Glutaraldehyde, except when included in Schedule 2 or 5
Glyceryl thioglycollate in hair waving preparations, unless the directions for use include the statement—
“WEAR PROTECTIVE GLOVES WHEN USING.  KEEP OUT OF EYES.”
Guazatine
Haloxon
Haloxyfop
Heptachlor
Hexachlorophane in preparations for the treatment of animals
Hydramethylnone, except when included in Schedule 5
Hydrazine
Hydrochloric acid (excluding its salts and derivatives), except in preparations containing 10% or less of hydrochloric acid (HCl)
Hydrofluoric acid (including hydrosilicofluoric acid but excluding their salts and derivatives) in preparations containing the equivalent of 10% or less of hydrogen flouride, except when included in Schedule 5
Hydroquinone, except—
	(a)	when included in Schedule 2 or 4; or
	(b)	in preparations containing 10% or less of hydroquinone
Hydrosilicofluoric acid—see Hydrofluoric acid
Hygromycin for use as an anthelmintic in animal feed premixes containing 2% or less of antibiotic substances
Imidocarb
Iodine (excluding its salts, derivatives and iodophors), except—
	(a)	when included in Schedule 2; or
	(b)	in solid or semi-solid preparations containing 2.5% or less of available iodine
Iodophors, except in preparations containing 1.5% or less of available iodine
Ioxynil
Iron compounds for the treatment of animals, except—
	(a)	in liquid or gel preparations containing 0.1% or less of iron; or
	(b)	in animal feeds and feed premixes
Isoconazole for the external treatment of animals
Isocyanates, free organic
Ivermectin—
	(a)	in preparations containing 0.8 g/litre of ivermectin for the treatment of sheep;
	(b)	in pre-loaded syringes containing 10 g or less of a paste containing 2% or less of ivermectin for the treatment of horses; or
	(c)	in preparations containing 1% or less of ivermectin, for the treatment of bovine cattle, when supplied in sealed containers for use in automatic injection equipment
Kitasamycin in animal feed premixes for growth promotion containing 2% or less of antibiotic substances
Lasalocid, except in animal feeds containing 100 mg/kg or less of antibiotic substances
Laurylisoquinolinium bromide
Lead compounds, except—
	(a)	when included in Schedule 4 or 5;
	(b)	in preparations for cosmetic use containing 100 mg/kg or less of lead; or
	(c)	in pencil cores, finger colours, showcard colours, pastels, crayons, poster paints, poster colours or coloured chalks when these products contain 100 mg/kg or less of lead
Levamisole for the treatment of animals, except—
	(a)	when included in Schedule 4 or 5; or
	(b)	in preparations for the treatment of ornamental birds or ornamental fish in packs containing 10 mg or less of levamisole
Lindane, except when included in Schedule 2, 4 or 5
Maduramicin in animal feed premixes containing 1% or less of antibiotic substances
Mafenide for the treatment of aquarium fish
Maldison, except—
	(a)	when included in Schedule 2, 4 or 5; or
	(b)	in dust preparations containing 2% or less of maldison
Mebendazole for the treatment of animals
Meclofenamic acid for the treatment of animals
Mefluidide
Melaleuca oil (tea-tree oil), except in preparations containing 25% or less of melaleuca oil
Menazon
Mercuric oxide for the treatment of animals, in preparations for ocular use
Mercuric thiocyanate when prepared for use for photographic purposes
Mercurochrome for the treatment of animals, in preparations for topical use
Metacresolsulphonic acid and formaldehyde condensation product for the treatment of animals
Metaldehyde, except when included in Schedule 5
Metham
Methanol (excluding its derivatives), except—
	(a)	when included in Schedule 5; or
	(b)	in preparations containing 2% or less of methanol
Methazole
Methiocarb, except when included in Schedule 5
Methomyl in fly-baits containing 1% or less of methhomyl and not less than 0.002% of denatonium benzoate as a bittering agent
Methyl chloride
Methylenebisthiocyanate, except in preparations containing 1% or less of methylenebisthiocyanate
Methyl isothiocyanate
Methyl salicylate excluding admixtures
Miconazole for the external treatment of animals
Molinate
Monensin—
	(a)	in animal feed premixes for growth promotion or for coccidiosis prevention containing 12.5% or less of monensin; or
	(b)	in intraruminal implants for cattle each containing 35 g or less of monensin
MSMA in herbicides or defoliant preparations, except when included in Schedule 5 
Nabam
Naled, except when included in Schedule 5
Nalidixic acid when packed and labelled for the treatment of ornamental fish
Naphthalophos when specifically prepared and packed for use as a sheep drench
Narasin in animal feed premixes containing 120 g/kg or less of narasin
Neomycin in preparations for topical application to animals for ocular use only
Nicotine in preparations containing 3% or less of nicotine, when packed and labelled for the treatment of animals
Nimidane in preparations containing 25% or less of nimidane
Nithiamide, except in preparations containing 20% or less or nithiamide
Nitric acid (excluding its salts and derivatives), except in preparations containing 10% or less of nitric acid as such
Nitrobenzene, except—
	(a)	in solid or semi-solid polishes;
	(b)	in soaps containing 1% or less of nitrobenzene; or
	(c)	in other preparations containing 0.1% or less of nitrobenzene
Nitrophenols, ortho, meta and para
Nitroscanate
Nitroxynil
Novobiocin in preparations for intramammary infusion in animals containing not more than 100 000 I.U. of novobiocin per dose, when packed in an applicator device specially designed for intramammary infusion and suitably coloured with no less than 25 mg per dose of Brilliant Blue FCF so that the visual end point excludes 95% of excreted antibiotic
Ochtilinone—see 2-Octyl-4-isothiazolin-3-one
2-Octyl-4-isothiazolin-3-one (octhilinone)
Oestradiol—
	(a)	in ear implants for growth promotion in bovine cattle; or
	(b)	in combination with progesterone, testosterone or trenbolone in ear implants for growth promotion in bovine cattle
Olaquindox in animal feed premixes for growth promotion
Oleandomycin in animal feed premixes for growth promotion containing 2% or less of antibiotic substances
Omethoate in preparations containing 50% or less of omethoate
Organo-tin compounds—see Tin organic compounds
Oxadiazon
Oxalic acid, except its derivatives and insoluble salts
Oxantel embonate for the treatment of animals
Oxfendazole
Oxyclozanide
Oxytetracycline in preparations—
	(a)	for topical application to animals for ocular use only; or
	(b)	for intramammary infusion in animals containing not more than 100 000 I.U. of oxytetracycline per dose, when packed in an applicator device specially designed for intramammary infusion and suitably coloured with no less than 25 mg per dose of Brilliant Blue FCF so that the visual end point excludes 95% of excreted antibiotic
Parbendazole
Pentachlorophenol, except in preparations containing 0.5% or less of pentachlorophenol
Peracetic acid, except when included in Schedule 5
Perfluidone
Permanganates
Phenethicillin in preparations for intramammary infusion in animals containing not more than 100 000 I.U. of phenethicillin per dose, when packed in an applicator device specially designed for intramammary infusion and suitably coloured with no less than 25 mg per dose of Brilliant Blue FCF so that the visual end point excludes 95% of excreted antibiotic
Phenol, or any homologue of phenol boiling below 220°C, except—
	(a)	when included in Schedule 2; or
	(b)	in preparations containing 3% or less of such substances
Phenothiazine (excluding its derivatives), except in preparations containing 10% or less of phenothiazine
Phenoxymethylpenicillin in preparations for intramammary infusion in animals containing not more than 100 000 I.U. of phenoxymethylpenicillin per dose, when packed in an applicator device specially designed for intramammary infusion and suitably coloured with no less than 25 mg per dose of Brilliant Blue FCF so that the visual end point excludes 95% of excreted antibiotic
Phenylenediamines and alkylated phenylenediamines not elsewhere specified in this Schedule or in Schedule 2—
	(a)	when used in hair dyes;
	(b)	in preparations packed and labelled for photographic purposes; or
	(c)	in preparations packed and labelled for testing water, except in tablets containing 10 mg or less of diethyl-para-phenylenediamine or dimethyl-para-phenylenediamine in opaque strip packaging provided the directions for use include the statement—
		“DO NOT DISCARD TESTING SOLUTIONS INTO THE POOL”
Phosalone
Phosmet
Phosphides, metallic
Phoxim
Picric acid (excluding its derivatives), except in preparations containing 5% or less of picric acid
Pindone
Piperophos
Pirimicard, except when included in Schedule 5
Pirimiphos-ethyl
Pirimiphos-methyl
Potassium bromate, except in preparations containing 0.5% or less of potassium bromate
Potassium cyanate
Potassium hydroxide (excluding its salts and derivatives), except—
	(a)	when included in Schedule 5; or
	(b)	in preparations containing 0.5% or less of potassium hydroxide
Prochloraz
Profenofos
Progesterone—
	(a)	in a silicone rubber elastomer when used as a controlled-release implant for synchronisation of oestrus in cattle; or
	(b)	in combination with oestradiol or trenbolone, in ear implants for growth promotion in bovine cattle
Promacyl
Promecarb in preparations containing 50% or less of promecarb
Propachlor
Propargite
Propetamphos
Propiconazole, except when included in Schedule 5
Propineb
Propionic acid (excluding its salts and derivatives), except—
	(a)	when included in Schedule 5;
	(b)	in preparations containing 30% or less of propionic acid; or
	(c)	for therapeutic use
Propoxur, except when included in Schedule 4 or 5
Propylene oxide in preparations containing 4% or less of propylene oxide
Prothiofos
Pyrazophos
Rafoxanide
Salinomycin in animal feed premixes containing 6% or less of antibiotic substances
Selenium—
	(a)	in preparations containing 2.5% or less of selenium when packed and labelled—
	(i)	for the blueing of gun barrels; or
	(ii)	for photographic purposes;
	(b)	in coated fertiliser granules containing 1% or less of selenium, except in fertilisers containing 200 g/tonne or less of selenium;
	(c)	in a drench, injection, paste, stock lick or vaccine containing 0.5% or less of selenium for the treatment of animals; or
	(d)	in animal feed premixes containing 2% or less of selenium for the preparation of feeds containing 0.1 g/tonne or less of selenium
Silver nitrate, except—
	(a)	when included in Schedule 2; or
	(b)	in chewing tablets
Sodium bromate, except in preparations containing 0.5% or less of sodium bromate
Sodium hydroxide (excluding its salts and derivatives), except—
	(a)	when included in Schedule 5; or
	(b)	in preparations containing 0.5% or less of sodium hydroxide
Spiramycin in animal feed premixes for growth promotion containing 2% or less of antibiotic substances
Streptomycin in preparations for intramammary infusion in animals containing not more than 100 000 I.U. of streptomycin per dose, when packed in an applicator device specially designed for intramammary infusion and suitably coloured with no less than 25 mg per dose of Brilliant Blue FCF so that the visual end point excludes 95% of excreted antibiotic
Sulcofuron in preparations for the treatment of carpets during manufacture
Sulphaquinoxaline when packed and labelled for use as a coccidiostat in poultry, except preparations containing 200 mg/kg or less of sulphaquinoxaline
Sulphonamides when packed and labelled for the treatment for ornamental caged birds or ornamental fish only
Sulphuric acid (excluding its salts and derivatives), except—
	(a)	in fire extinguishers; or
	(b)	in preparations containing 0.5% or less of sulphuric acid
Sulprophos
2,4,5-T
TCA—see Trichloroacetic acid
TCMTB (2-[thiocyanomethylthio]benzothiazole)
TDE (1,1-dichloro-2,2-bis(4-chlorophenyl)ethane), except when included in Schedule 5
Tea-tree oil—see Melaleuca oil
Temephos, except when included in Schedule 5
Terbuthylazine
Terpenes, chlorinated
Testosterone—
	(a)	testosterone cypionate, dipropionate, enanthate and propionate in preparations labelled for treatment and prevention of pizzle (sheath) rot in wethers;
	(b)	in preparations labelled for masculinisation of wethers for use as ‘teaser rams’ to stimulate and detect reproductive activity in ewes;
	(c)	in combination with oestradiol or trenbolone in ear implants for growth promotion in bovine cattle; or
	(d)	in oil preparations for growth promotion purposes labelled for injection at the base of the ear in sheep
Tetrachloroethylene, except—
	(a)	when included in Schedule 5;
	(b)	in preparations containing 6% or less of tetrachloroethylene when absorbed into an inert solid;
	(c)	for therapeutic use; or
	(d)	in containers having a capacity of more than 25 litres which are labelled “POISON” and state the proportion of tetrachloroethylene
Tetracycline in preparations—
	(a)	for topical application to animals for ocular use only;
	(b)	for intramammary infusion in animals containing not more than 100 000 I.U. of tetracycline per dose, when packed in an applicator device specially designed for intramammary infusion and suitably coloured with no less than 25 mg per dose of Brilliant Blue FCF so that the visual end point excludes 95% of excreted antibiotic; or
	(c)	when packed and labelled for treatment of ornamental caged birds or ornamental fish only
Tetradifon
2,2’,6,6’-Tetraisopropyl-diphenyl-carbodiimide in amitraz formulations containing 2% or less of 2,2’,6,6’-tetraisopropyl-diphenyl-carbodiimide
2,2,3,3-Tetrafluoropropionic acid (flupropanate)
Tetramisole in preparations for the treatment of animals
Thiazafluron
Thiodicarb
Thiometon
Thiourea and alkyl thioureas, except for therapeutic use
Thiram
Tiamulin for the treatment of animals—
	(a)	in feed premixes containing 25% or less of tiamulin; or
	(b)	in soluble concentrates containing 45% or less of tiamulin
Tin organic compounds, being di-alkyl, tri-alkyl and tri-phenyl tin compounds where the alkyl group is methyl, ethyl, propyl or butyl, except—
	(a)	when separately specified in this Schedule;
	(b)	in plastics; or 
	(c)	in paints containing 1% or less of tin
Toluene (excluding its derivatives), except—
	(a)	in preparations containing 50% or less of toluene or toluene and xylene; or
	(b)	in containers having a capacity of more than 25 litres which are labelled “POISON” and state the proportion of toluene or toluene and xylene
Trenbolone—
	(a)	in ear implants for growth promotion in bovine cattle; or
	(b)	in combination with oestradiol, progesterone or testosterone in ear implants for growth promotion in bovine cattle
Triadimefon, except—
	(a)	when included in Schedule 5; or
	(b)	in fertilisers containing 5 g/kg or less of triadimefon 
Trichlorfon
Trichloroacetic acid, except when included in Schedule 5
Trichloroethylene, except when included in Schedule 4
Trichlorophenol
Triclopyr
Tridemorph
Triethyl phosphate
Trifluoromethane sulphonic acid
Tylosin in animal feed premixes for growth promotion containing 5% or less of antibiotic substances
Vamidothion
Virginiamycin in animal feed premixes for growth promotion containing 2% or less of antibiotic substances
Warfarin, except—
	(a)	when included in Schedule 4 or 5; or
	(b)	for external therapeutic use
Xylene (excluding its derivatives), except—
	(a)	in preparations containing 50% or less of xylene or xylene and toluene; or
	(b)	in containers having a capacity of more than 25 litres which are labelled “POISON” and state the proportion of xylene or xylene and toluene
Zeranol in ear implants for use as a growth promotant in steer cattle 
Zinc chloride, except in preparations containing 5% or less of zinc chloride
Zinc p-phenolsulphonate, except in preparations containing 5% or less of zinc p‑phenolsulphonate
Zinc sulphate, except—
	(a)	when included in Schedule 4;
	(b)	in preparations for human internal use with a recommended daily dose of 50 mg or less of zinc; or
	(c)	in other preparations containing 5% or less of zinc sulphate

	SCHEDULE 7	Section 3
Acrolein
Acrylonitrile
Alachlor
Aldicarb
Aldoxycarb
Allyl alcohol
Aminocarb, except when included in Schedule 6
4-Aminopyridine, except when included in Schedule 4
Amiton
Arprinocid

Arsenic, except—
	(a)	thiacetarsamide when included in Schedule 4;
	(b)	when included in Schedule 5 or 6;
	(c)	selenium arsenide in photocopier drums; or
	(d)	in animal feeds containing 75 g/tonne or less of arsenic
Avermectin B1, except when included in Schedule 6
Azinphos-ethyl
Azinphos-methyl
Azocyclotin
Bendiocarb, except when included in Schedule 5 or 6
Benzene (excluding its derivatives), except—
	(a)	preparations containing 15 ml/litre or less of benzene; or
	(b)	petrol containing 50 ml/litre or less of benzene
Brodifacoum, except when included in Schedule 6
Bromadiolone, except when included in Schedule 6
Bromethalin, except when included in Schedule 6
Bromine, excluding its salts and derivatives
Brucine, except when used in concentrations of 0.02% or less for the denaturation of alcohol
Calciferol for use as a rodenticide, except when included in Schedule 6
Captafol
Captan
Carbadox
Carbofuran
Carbon tetrachloride, except in chlorinated rubber based paints containing less that 1% of carbon tetrachloride
Carbophenothion
Chlordecone
Chlordimeform
Chlorfenvinphos
Chlorine, excluding its salts and derivatives
Chloromethiuron 
5-Chloro-3-methyl-4-nitropyrazole
4-Chloro-o-toluidine
Chloropicrin, except when included in Schedule 6
Chlorthiophos
Cholecalciferol for use as a rodenticide, except when included in Schedule 6
Coumaphos, except when included in Schedule 6
Cyanides, except—
	(a)	ferricyanides; or
	(b)	ferrocyanides
Cyhalothrin
Cyhexatin
Deltamethrin, except when included in Schedule 5
Demeton
Demeton-O-methyl, except when included in Schedule 6
Demeton-S-methyl, except when included in Schedule 6
Dialifos
4,4-Diaminodiphenylmethane (methylene dianiline)
1,2-Dibromo-3-chloropropane
1,3-Dichloropropene
Dichlorvos, except when included in Schedule 5 or 6
Dicrotophos
Dienochlor
Difenacoum, except when included in Schedule 6
Dimefox
1,3-Di (methoxycarbonyl)-1-propen-2-yl-dimethyl phosphate, except when included in Schedule 6
N,N-Dimethyl-4-(phenylazo)-benzamine
Dimethyl sulphate
Dimetilan
Dinitrocresols, except when included in Schedule 4 or 6
Dinitrophenols, except when included in Schedule 4 or 6
Dinoseb
Disulfoton, except when included in Schedule 6
Endothal, except when included in Schedule 6
Endrin
Epichlorohydrin
Etaconazole
Ethion
Ethoprophos, except when included in Schedule 6
Ethylene dibromide
Ethylene oxide
Famphur, except when included in Schedule 6
Fenaminosulf, except when included in Schedule 6
Fenamiphos, except when included in Schedule 6
Fenoxacarim, except—
	(a)	when included in Schedule 6; or
	(b)	in treated carpets
Fensulfothion
Fenthion-ethyl
Flucofuron, except—
	(a)	when included in Schedule 6; or
	(b)	in treated carpets
Flucythrinate
Fluoroacetamide
Fluoroacetic acid
Folpet
Formetanate
Halofuginone, except in prepared stockfeeds containing 3 g/tonne or less of halofuginone
Halogenated dibenzodioxins and dibenzofurans
HCB
Hydrocarbons liquid aromatic (including aromatic extract oils), any fraction of which boils above 350°C, except when in solid polymers
Hydrocyanic acid (excluding its salts and derivatives), except when included in Schedule 4
Hydrofluoric acid (including hydrosilicofluoric acid but excluding their salts and derivatives), except when included in Schedule 5 or 6
Hydrogen sulphide
Isocarbophos
Isofenphos
Ivermectin, except when included in Schedule 4 or 6
Leptophos
Maduramicin, except when included in Schedule 6
Mazidox
Mecarbam
Mercuric chloride when prepared for use for agricultural, industrial, pastoral or horticultural purposes
Mercury, except—
	(a)	when separately specified in this Schedule;
	(b)	when included in Schedule 2, 4 or 6;
	(c)	in preparations containing 0.01% or less of mercury in organic form as a preservative;
	(d)	mercury (metallic) in scientific instruments; or
	(e)	dental amalgams
Methacrifos
Methamidophos
Methapyrilene
Methidathion
Methomyl, except when included in Schedule 6
Methyl bromide
4,4´-Methylenebis[2-chloroaniline] (MOCA)
Mevinphos
Mipafox
Mirex
Monocrotophos
Naphthalophos, except when included in Schedule 6
Nicotine, except—
	(a)	when included in Schedule 3, 4 or 6; or
	(b)	in tobacco prepared and packed for smoking
Nimidane, except when included in Schedule 6
Nitrofen
Omethoate, except when included in Schedule 6
Oxamyl
Oxyfluorfen
Paraquat
Parathion
Parathion-methyl
Phorate
Phosfolan
Phosphine
Phosphorus, yellow (excluding its salts and derivatives)
Polychlorinated biphenyls
Promecarb, except when included in Schedule 6
Propylene oxide, except when included in Schedule 6
Pyrinuron
Schradan
Selenium, except—
	(a)	when included in, or expressly excluded from, Schedule 4, 5 or 6; or
	(b)	as selenium arsenide in photocopier drums
Strychnine (including Nux vomica), except when included in Schedule 4
Sulcofuron, except—
	(a)	when included in Schedule 6; or
	(b)	in treated carpets
Sulfotep
TEPP
Terbufos
Tetrachloroethane
2,2´, 6,6´-Tetraisopropyl-diphenyl-carbodiimide, except when included in Schedule 6
Thallium
Thiofanox
ortho-Tolidine
Triamiphos
Triazbutil
Trichloroisocyanuric acid, except—
	(a)	when included in Schedule 5; or
	(b)	in preparations containing 4% or less of available chlorine
Vinyl chloride

NOTE
1.	Ordinance No. 38, 1978 as amended by Nos. 19 and 56, 1981; No. 47, 1982; No. 67, 1985; Nos. 32 and 76, 1986; No. 29, 1988; Nos. 13, 21 and 38, 1989.
[Presentation speech made in Assembly on 13 December 1990.]

©  Australian Capital Territory 1991